[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1423
1. Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE, Rubin MA, Witte ON: Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate; 2010 Apr 1;70(5):491-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo.
  • They may be targets for tumor initiation, so characterization of these cells may have therapeutic implications.
  • Subpopulations of prostate epithelial cells were isolated by cell sorting and interrogated for sphere-forming activity.
  • RESULTS: Prostate tissue specimens were heterogeneous, containing both benign and malignant (Gleason 3-5) glands.
  • Subpopulations of prostate cells expressing tumor-associated calcium signal transducer 2 (Trop2), CD44, and CD49f preferentially formed spheres.
  • The TMPRSS-ERG fusion was absent in prostaspheres derived from fusion-positive tumor tissue, suggesting a survival/growth advantage of benign prostate epithelial cells.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] Br J Cancer. 2000 Feb;82(4):990-7 [10732776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20882-7 [19088204.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):590-9 [11506501.001]
  • [Cites] J Cell Sci. 2001 Nov;114(Pt 21):3865-72 [11719553.001]
  • [Cites] J Pathol. 2001 Dec;195(5):563-70 [11745692.001]
  • [Cites] Mol Cancer Res. 2002 Dec;1(2):113-21 [12496358.001]
  • [Cites] Genes Dev. 2003 May 15;17(10):1253-70 [12756227.001]
  • [Cites] Brain Res. 2003 Dec 12;993(1-2):18-29 [14642827.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3029-35 [14701873.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3539-45 [15226377.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):209-14 [15368472.001]
  • [Cites] J Neurosci Res. 2004 Oct 15;78(2):215-23 [15378509.001]
  • [Cites] J Steroid Biochem Mol Biol. 1996 Nov;59(3-4):243-50 [9010316.001]
  • [Cites] Differentiation. 1998 Jul;63(3):131-40 [9697307.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):1005-12 [9744319.001]
  • [Cites] J Cell Physiol. 1999 Nov;181(2):304-11 [10497309.001]
  • [Cites] Acta Biochim Pol. 2005;52(2):353-8 [15990920.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9269-79 [16230388.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Nat Med. 2006 Mar;12(3):296-300 [16520777.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1880-5 [16574858.001]
  • [Cites] Cancer Cell. 2006 May;9(5):367-78 [16697957.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1213-8 [16632344.001]
  • [Cites] Brain Res. 2006 Aug 30;1107(1):82-96 [16859652.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8598-607 [16951173.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Nat Methods. 2006 Oct;3(10):801-6 [16990812.001]
  • [Cites] Mol Carcinog. 2007 Jan;46(1):1-14 [16921491.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):181-6 [17185413.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Prostate. 2007 Sep 15;67(13):1384-96 [17639507.001]
  • [Cites] Dev Biol. 2007 Dec 1;312(1):396-406 [17976567.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9703-11 [19047148.001]
  • [Cites] Prostate. 2001 Feb 1;46(2):142-53 [11170142.001]
  • (PMID = 19938015.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16042; United States / NIAID NIH HHS / AI / AI-28697; United States / NHGRI NIH HHS / HG / F31 HG000117; United States / NCI NIH HHS / CA / P30 CA016042; United States / NHGRI NIH HHS / HG / HG000117-05; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NHGRI NIH HHS / HG / F31 HG000117-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD44; 0 / CD44 protein, human; 0 / Glycoproteins; 0 / Integrin alpha6; 0 / Oncogene Proteins, Fusion; 0 / Peptides; 0 / TMPRSS2-ERG fusion protein, human
  • [Other-IDs] NLM/ NIHMS187861; NLM/ PMC2885946
  •  go-up   go-down


2. Fan DM, Shi HR, Chen ZM, Liu HN, Zhang RT: [Expression of TGF-beta1 and E-cadherin in primary and metastatic ovarian carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun;30(6):1355-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Immunohistochemistry (IHC) was performed to detect the expression of TGF-beta1 and E-cadherin proteins in primary and metastatic ovarian carcinoma, benign epithelial ovarian tumor and normal ovarian tissue.
  • RESULTS: The expression of TGF-beta1 was significantly higher in ovarian carcinoma (67.2%) than in benign tumors (28.6%) and normal ovarian tissue (18.9%) (Chi2=26.94, P<0.001), but E-cadherin expression showed a reverse pattern.
  • TGF-beta1 expression in the primary ovarian carcinoma carcinoma was associated with the FIGO stage, lymph metastasis and ascites of the tumor (P=0.01, P=0.01, and P=0.04, respectively).
  • E-cadherin expression in the tumor was associated with the differentiation (P=0.02) and lymph metastasis of ovarian carcinoma (P=0.04).
  • The expressions of TGF-beta1 and E-cadherin were all significantly lower in the primary tumors than in the metastatic tumor (Chi2=4.70, P=0.03; Chi2=5.91, P=0.015).
  • [MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584638.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


3. Yigitbasi R, Karabicak I, Aydogan F, Erturk S, Bican O, Aydin O, Kantarci F: Benign splenic epithelial cyst accompanied by elevated Ca 19-9 level: a case report. Mt Sinai J Med; 2006 Oct;73(6):871-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign splenic epithelial cyst accompanied by elevated Ca 19-9 level: a case report.
  • We report the case of a 30-year-old woman with a benign epidermoid splenic cyst and a high CA 19-9 serum level (268 U/mL).
  • Approximately 30 cases of benign true splenic cysts with a high CA 19-9 serum level have been published.
  • [MeSH-major] CA-19-9 Antigen / blood. Epidermal Cyst / surgery. Splenectomy. Splenic Diseases / surgery
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Female. Humans. Spleen / pathology. Spleen / surgery

  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117313.001).
  • [ISSN] 0027-2507
  • [Journal-full-title] The Mount Sinai journal of medicine, New York
  • [ISO-abbreviation] Mt. Sinai J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


Advertisement
4. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ: Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res; 2005 Aug 01;65(15):6640-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
  • Putative prostate stem cells and prostate tumor stem cells in benign and malignant human prostate tissue, in primary human prostate xenografts, and in the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model of prostate cancer, are defined by expression of breast cancer resistance protein (BCRP), a marker of pluripotent hematopoietic, muscle, and neural stem cells, and by an absence of androgen receptor (AR) protein.
  • In both benign and malignant human prostate tissue, the rare epithelial cells that express BCRP and lack AR protein are localized in the basal cell compartment, survive androgen deprivation, and maintain proliferative potential in the hypoxic, androgen-deprived prostate.
  • Putative prostate tumor stem cells that express BCRP but not AR protein in TRAMP are the source of a BCRP-negative and AR-negative, Foxa2- and SV40Tag-expressing, transit amplifying compartment that progresses to the poorly differentiated carcinomas that arise rapidly after castration.
  • Therefore, BCRP expression isolates prostate stem/tumor stem cells from the prostate tissue microenvironment through constitutive efflux of androgen, protecting the putative tumor stem cells from androgen deprivation, hypoxia, or adjuvant chemotherapy, and providing the nidus for recurrent prostate cancer.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. Androgens / metabolism. Neoplasm Proteins / biosynthesis. Neoplastic Stem Cells / metabolism. Prostatic Neoplasms / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NOVOBIOCIN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061644.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA84296; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA77739; United States / NCI NIH HHS / CA / CA64851; United States / NIEHS NIH HHS / ES / ES07017; United States / NCI NIH HHS / CA / CA64865
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Androgens; 0 / Indoles; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Androgen; 17EC19951N / Novobiocin; CW5S8OP3VO / tryptoquivaline
  •  go-up   go-down


5. Mortuaire G, Pasquesoone X, Leroy X, Chevalier D: Respiratory epithelial adenomatoid hamartomas of the sinonasal tract. Eur Arch Otorhinolaryngol; 2007 Apr;264(4):451-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Respiratory epithelial adenomatoid hamartomas of the sinonasal tract.
  • We report the clinicopathologic features of two cases of respiratory epithelial adenomatoid harmartoma (REAH) of the sinonasal tract.
  • Histologically, these lesions were characterized by a glandular proliferation lined by ciliated respiratory epithelium originated from the surface epithelium.
  • Fine histopathological analysis is necessary to avoid aggressive surgery for this benign lesion.
  • [MeSH-major] Adenomatoid Tumor / pathology. Hamartoma / pathology. Paranasal Sinus Neoplasms / pathology. Respiratory Mucosa / pathology
  • [MeSH-minor] Adult. Endoscopy. Female. Humans. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 May;97(5):607-12 [15153874.001]
  • [Cites] Am J Otolaryngol. 2004 Jul-Aug;25(4):282-4 [15239039.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Aug;104(8):639-45 [7639474.001]
  • [Cites] J Laryngol Otol. 2004 Jul;118(7):558-60 [15318966.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2003 Jun;67(6):669-72 [12745162.001]
  • [Cites] Acta Otolaryngol. 2002 Jun;122(4):398-400 [12125996.001]
  • [Cites] Rev Laryngol Otol Rhinol (Bord). 2004;125(1):45-8 [15244029.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2005 Jan;69(1):87-91 [15627453.001]
  • (PMID = 17089137.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Butnor KJ: My approach to the diagnosis of mesothelial lesions. J Clin Pathol; 2006 Jun;59(6):564-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelial lesions pose considerable diagnostic challenges not only because benign tumours, reactive proliferations and malignant mesothelioma can mimic one another, but also because the morphological patterns displayed by malignant mesothelioma can simulate a variety of epithelial and non-epithelial malignancies.
  • In adequately sampled lesions, however, the distinction between malignant mesothelioma, benign mesothelial proliferations and other tumours can be achieved in most cases by using a carefully integrated approach that incorporates clinical and radiographic data, immunohistochemical studies and, in selected cases, histochemical and ultrastructural techniques.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Biomarkers, Tumor / metabolism. Cell Proliferation. Diagnosis, Differential. Epithelium / pathology. Humans

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1997 Jul;31(1):25-30 [9253621.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1399-408 [9414183.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1409-19 [9414184.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):85-9 [9426522.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):166-9 [9490276.001]
  • [Cites] Cancer Lett. 1998 Feb 13;124(1):73-8 [9500194.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):285-92 [9580050.001]
  • [Cites] Histopathology. 1998 Mar;32(3):209-16 [9568505.001]
  • [Cites] Histopathology. 1998 May;32(5):462-72 [9639123.001]
  • [Cites] Histopathology. 2000 Sep;37(3):224-31 [10971698.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1545-9 [11090371.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):610-7 [11342772.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):246-52 [11488072.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):253-62 [11488073.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1316-20 [11570906.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1304-9 [11688466.001]
  • [Cites] Arch Pathol Lab Med. 2001 Dec;125(12):1588-90 [11735696.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):6-10 [11796835.001]
  • [Cites] Am J Clin Pathol. 1998 Aug;110(2):191-9 [9704618.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):182-8 [9754650.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1215-21 [9777983.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):929-33 [9796717.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):313-23 [10088551.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):105-10 [15389250.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Histopathology. 2003 Mar;42(3):270-9 [12605647.001]
  • [Cites] J Pathol. 2003 Apr;199(4):479-87 [12635139.001]
  • [Cites] Mod Pathol. 2003 Mar;16(3):192-7 [12640097.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):605-9 [12827615.001]
  • [Cites] J Thorac Imaging. 2003 Jul;18(3):200-3 [12867819.001]
  • [Cites] Histopathology. 2003 Sep;43(3):231-8 [12940775.001]
  • [Cites] Histopathology. 2003 Nov;43(5):444-52 [14636270.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):534-40 [15087673.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):697-710 [15188136.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):449-55 [15297187.001]
  • [Cites] Ann Thorac Surg. 2004 Nov;78(5):1774-6 [15511473.001]
  • [Cites] Am J Clin Pathol. 1976 Feb;65(2):159-67 [175652.001]
  • [Cites] Am J Pathol. 1982 Jul;108(1):80-8 [6178295.001]
  • [Cites] Am J Surg Pathol. 1982 Apr;6(3):215-22 [7102900.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):62-6 [3099726.001]
  • [Cites] Pathol Annu. 1987;22 Pt 2:91-131 [2825103.001]
  • [Cites] Ultrastruct Pathol. 1987;11(5-6):503-33 [3318058.001]
  • [Cites] Ultrastruct Pathol. 1988;12(4):367-84 [2458647.001]
  • [Cites] Pathol Annu. 1989;24 Pt 1:303-53 [2654842.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Histopathology. 2000 Apr;36(4):341-7 [10759948.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):292-6 [2295052.001]
  • [Cites] Hum Pathol. 1990 Jul;21(7):759-66 [2193875.001]
  • [Cites] Histopathology. 1992 Jan;20(1):47-51 [1310669.001]
  • [Cites] J Clin Pathol. 1992 Apr;45(4):295-8 [1577967.001]
  • [Cites] Histopathology. 1992 Nov;21(5):453-7 [1280615.001]
  • [Cites] Histopathology. 1993 Jun;22(6):601-2 [8354495.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):357-63 [7511353.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):439-45 [7513500.001]
  • [Cites] Hum Pathol. 1994 Aug;25(8):753-7 [7520015.001]
  • [Cites] Hum Pathol. 1995 Apr;26(4):428-31 [7535740.001]
  • [Cites] Semin Diagn Pathol. 1995 Feb;12(1):30-44 [7770673.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1124-37 [7573671.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):189-94 [8607443.001]
  • [Cites] Am J Surg Pathol. 1996 Sep;20(9):1037-46 [8764740.001]
  • [Cites] Pathol Res Pract. 1995 Nov;191(11):1147-52 [8822117.001]
  • [Cites] Ultrastruct Pathol. 2004 Jul-Aug;28(4):213-28 [15693633.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):75-9 [15722797.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):913-21 [15743802.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):372-80 [15891998.001]
  • [Cites] Hum Pathol. 2005 May;36(5):465-73 [15948112.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):866-73 [15958850.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):34-48 [16056246.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1203-14 [9777982.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5):649-54 [10800396.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):184-93 [10968704.001]
  • [Cites] J Postgrad Med. 2002 Jan-Mar;48(1):29-31 [12082324.001]
  • [Cites] Histopathology. 2002 Jul;41(1):42-9 [12121236.001]
  • [Cites] Histopathology. 2002 Oct;41(4):301-7 [12383211.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):150-8 [12548160.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3443-8 [12552937.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):193-5 [12562233.001]
  • [Cites] Chest. 1997 Jan;111(1):106-9 [8996002.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):29-34 [10665909.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):107-12 [10697265.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):598-606 [10757409.001]
  • (PMID = 16731600.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1860395
  •  go-up   go-down


7. Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW: Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res; 2007 May 1;67(9):4244-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.
  • The present study explores the mechanisms by which human prostatic carcinoma-associated fibroblasts (CAF) induce tumorigenesis in initiated but nonmalignant human prostatic epithelial cells (BPH-1).
  • The SDF-1 receptor, CXCR4, is expressed at low levels in benign prostate tissue and in BPH-1 cells in culture.
  • Suppression of epithelial cell CXCR4 expression abrogated the tumorigenic response to CAF.
  • SDF-1, secreted by CAF, acts via the TGF-beta-regulated CXCR4 to activate Akt in the epithelial cells.
  • Thus, tumor stroma can contribute to carcinogenesis through synergism between TGF-beta, SDF-1, and CXCR4.
  • These experiments suggest mechanisms by which TGF-beta can shift its role from an inhibitor to a promoter of proliferation during tumor progression.
  • [MeSH-minor] Animals. Cell Communication / physiology. Chemokine CXCL12. Culture Media, Conditioned. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Fibroblasts / metabolism. Fibroblasts / pathology. Humans. Male. Pregnancy. Rats. Rats, Sprague-Dawley. Signal Transduction. Stromal Cells / metabolism. Stromal Cells / pathology. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483336.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA126505; United States / NCI NIH HHS / CA / CA96403; United States / NIDDK NIH HHS / DK / DK067049; United States / NCI NIH HHS / CA / P30CA68485
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Culture Media, Conditioned; 0 / Receptors, CXCR4; 0 / Transforming Growth Factor beta
  •  go-up   go-down


8. Petri AL, Simonsen AH, Høgdall E, Christensen IJ, Kjaer SK, Yip C, Risum S, Pedersen AT, Hartwell D, Fung ET, Høgdall C: Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. Proteomics Clin Appl; 2010 Mar;4(3):304-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The purposes of this study were to confirm previously found candidate epithelial ovarian cancer biomarkers in urine and to compare a paired serum biomarker panel and a urine biomarker panel from the same study cohort with regard to the receiver operating characteristic curve (ROC) area under the ROC curve (AUC) values.
  • RESULTS: Multivariate analysis of the urine panel demonstrated a significant differentiation (p<0.0001) between epithelial ovarian cancer patients and patients with benign ovarian pelvic masses.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / urine. Proteomics / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasms, Glandular and Epithelial / blood. Neoplasms, Glandular and Epithelial / diagnosis. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / urine. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / urine. Tandem Mass Spectrometry. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 21137051.001).
  • [ISSN] 1862-8354
  • [Journal-full-title] Proteomics. Clinical applications
  • [ISO-abbreviation] Proteomics Clin Appl
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Ovarian epithelial cancer
  •  go-up   go-down


9. Ma L, Guo Q, Ma Y, Liu FR, Shen XY: Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers. Eur J Gynaecol Oncol; 2009;30(4):370-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers.
  • METHODS: In this study, we detected the frequency of promoter hypermethylation of the RASSF1A gene in 60 patients with primary serous epithelial ovarian carcinomas (SEOCs) using Methylation-Specific PCR (MSP).
  • RESULTS: The frequency of promoter hypermethylation of RASSF1A in Chinese primary SEOCs was 53.3%, whereas promoter hypermethylation was not found in normal ovarian tissues and benign ovarian tissues.
  • [MeSH-major] Gene Silencing. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761124.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


10. Zhao H, Nolley R, Chen Z, Peehl DM: Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol; 2010 Jul;177(1):229-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both benign and cancer tissues displayed characteristic histology and expression of cell-type specific markers for up to 3 months.
  • Finally, many normal secretory epithelial cells and cancer cells in TSGs remained viable 2 months after androgen ablation, consistent with similar observations in postprostatectomy specimens following neoadjuvant androgen ablation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 15;88(2):407-15 [10640975.001]
  • [Cites] BJU Int. 2010 Feb;105(4):462-7 [19624594.001]
  • [Cites] Prostate. 2003 Feb 15;54(3):212-9 [12518326.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2522-31 [12791667.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):440-8 [14760063.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1712-21 [14996731.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):290-7 [15017584.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]
  • [Cites] Prostate. 2004 Jul 1;60(2):77-90 [15162374.001]
  • [Cites] Br J Dermatol. 1983 Mar;108(3):321-6 [6830698.001]
  • [Cites] Am J Surg Pathol. 1994 Oct;18(10):979-91 [7522415.001]
  • [Cites] Life Sci. 1995;57(21):1887-901 [7475939.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):86-93 [8540613.001]
  • [Cites] Mod Pathol. 1996 Oct;9(10):1015-9 [8902840.001]
  • [Cites] J Urol. 2005 Jan;173(1):10-20 [15592017.001]
  • [Cites] J Urol. 2005 Feb;173(2):342-59 [15643172.001]
  • [Cites] J Urol. 2005 Feb;173(2):360-72 [15643173.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):19-47 [15788637.001]
  • [Cites] Prostate. 2005 Jul 1;64(2):149-59 [15678503.001]
  • [Cites] JAMA. 2005 Jul 13;294(2):238-44 [16014598.001]
  • [Cites] J Nutr. 2005 Dec;135(12 Suppl):3009S-3015S [16317162.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2815-25 [16510604.001]
  • [Cites] Cancer Cell. 2006 May;9(5):367-78 [16697957.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):105-7 [17227991.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 24;104(17):7211-6 [17431037.001]
  • [Cites] J Urol. 2007 Jun;177(6):2132-5; discussion 2135 [17509298.001]
  • [Cites] Curr Med Res Opin. 2007 May;23(5):1077-80 [17519074.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(2):114-8 [17297502.001]
  • [Cites] J Biol Chem. 2007 Aug 31;282(35):25790-800 [17602165.001]
  • [Cites] Clin Adv Hematol Oncol. 2008 Feb;6(2):118-22, 127-32 [18347563.001]
  • [Cites] Prostate. 2008 May 1;68(6):629-39 [18213636.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):448-54 [17720776.001]
  • [Cites] Cell Tissue Res. 2008 Jun;332(3):489-98 [18386065.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4447-54 [18519708.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6407-15 [18676866.001]
  • [Cites] J Urol. 2008 Sep;180(3):921-7 [18635218.001]
  • [Cites] Curr Oncol Rep. 2008 Nov;10(6):529-32 [18928669.001]
  • [Cites] Cancer Lett. 2009 Jan 18;273(2):177-93 [18632203.001]
  • [Cites] Nature. 2008 Dec 11;456(7223):804-8 [18946470.001]
  • [Cites] J Natl Cancer Inst. 2009 Jan 7;101(1):6-8 [19116380.001]
  • [Cites] J Urol. 2009 Feb;181(2):615-9; discussion 619-20 [19091346.001]
  • [Cites] Am J Mens Health. 2008 Jun;2(2):178-89 [19477782.001]
  • [Cites] Nature. 2009 Sep 24;461(7263):495-500 [19741607.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):855-60 [11549578.001]
  • (PMID = 20472887.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K01 CA123532; United States / NCI NIH HHS / CA / CA123532; United States / NCI NIH HHS / CA / CA121460; United States / NCI NIH HHS / CA / R01 CA121460; United States / NCI NIH HHS / CA / CA123532-04; United States / NCI NIH HHS / CA / K01 CA123532-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2893666
  •  go-up   go-down


11. Saornil MA, Becerra E, Méndez MC, Blanco G: [Conjunctival tumors]. Arch Soc Esp Oftalmol; 2009 Jan;84(1):7-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Conjunctival tumors].
  • [Transliterated title] Tumores de la conjuntiva.
  • Conjunctival tumors are one of the most frequent of the eye and adnexa.
  • They comprise a large variety of conditions, from benign lesions such as nevus or papilloma, to malignant lesions such as epidermoid carcinoma or melanoma which may threaten visual function and the life of the patient.
  • They can arise from any cellular component, but the most frequent are of epithelial and melanocytic origin.
  • In this paper we review the clinical characteristics of the most frequent conjunctival tumors, and we discuss tumor management.
  • [MeSH-minor] Carcinoma / pathology. Carcinoma / surgery. Conjunctival Diseases / pathology. Conjunctival Diseases / surgery. Eye Enucleation. Eye Evisceration. Hematologic Neoplasms / pathology. Hematologic Neoplasms / surgery. Humans. Melanoma / pathology. Melanoma / surgery. Neoplasm Invasiveness. Nevus / pathology. Nevus / surgery. Papilloma / pathology. Papilloma / surgery. Precancerous Conditions / pathology. Precancerous Conditions / surgery. Sarcoma / pathology. Sarcoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173134.001).
  • [ISSN] 1989-7286
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 47
  •  go-up   go-down


12. Cariaga-Martinez AE, Lorenzati MA, Riera MA, Cubilla MA, De La Rossa A, Giorgio EM, Tiscornia MM, Gimenez EM, Rojas ME, Chaneton BJ, Rodríguez DI, Zapata PD: Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression. Adv Urol; 2009;:723831
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression.
  • Our studies have shown that epithelial expressions of both proteins, SHP-1 and SSTR2, in normal and benign hyperplasia are localized in the luminal side of duct and acinar cells.
  • In malignant prostate tissue, SHP-1 was diminished in 28/45 cases or absent in 12/45 cases, whereas SSTR2 epithelial was diminished in 38/45 cases or lost in only 2/45 cases.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2005 Jul;92(2):175-86 [15986128.001]
  • [Cites] Eur J Biochem. 2002 Jun;269(12):3057-64 [12071971.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1649-54 [10197642.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] Endocrinology. 1999 Feb;140(2):765-77 [9927304.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):7099-106 [9507021.001]
  • [Cites] Curr Top Microbiol Immunol. 1999;246:291-7; discussion 298 [10396068.001]
  • [Cites] Leuk Res. 1999 Apr;23(4):373-84 [10229324.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1947-53 [10213505.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4132-7 [9751625.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3845-50 [9520455.001]
  • [Cites] J Biol Chem. 1997 Sep 26;272(39):24448-54 [9305905.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):915-26 [11836342.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1495-505 [11583976.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1424-32 [11516103.001]
  • [Cites] J Physiol Paris. 2000 May-Aug;94(3-4):205-10 [11087998.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1137-46 [11021818.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):9180-5 [10900262.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jul;85(7):2564-71 [10902809.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2008 Aug;22(4):601-13 [18971121.001]
  • [Cites] Acta Oncol. 2009;48(3):401-10 [18759148.001]
  • [Cites] Prostate. 2000 Feb 1;42(2):150-60 [10617873.001]
  • [Cites] Adv Anat Pathol. 2008 Nov;15(6):319-31 [18948763.001]
  • [Cites] J Cell Biochem. 2008 Oct 15;105(3):703-11 [18680145.001]
  • [Cites] Oncol Rep. 2008 Sep;20(3):485-92 [18695896.001]
  • [Cites] Immunity. 2008 Jul 18;29(1):12-20 [18631453.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9453-4 [18621723.001]
  • [Cites] Histol Histopathol. 2007 Nov;22(11):1251-67 [17647198.001]
  • [Cites] Endocrinology. 2006 Jul;147(7):3530-8 [16601140.001]
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):111-7 [16625859.001]
  • [Cites] Endocr J. 2005 Oct;52(5):605-11 [16284440.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):1-13 [16129412.001]
  • [Cites] Biochem J. 1997 Jul 15;325 ( Pt 2):449-54 [9230127.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2566-9 [9253335.001]
  • [Cites] J Exp Med. 1997 Nov 3;186(9):1575-83 [9348315.001]
  • [Cites] FEBS Lett. 1997 Apr 7;406(1-2):42-8 [9109383.001]
  • [Cites] Curr Opin Cell Biol. 1997 Apr;9(2):205-12 [9069257.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):839-52 [9064344.001]
  • [Cites] Mol Cell Endocrinol. 1995 Sep 22;113(2):195-204 [8674827.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Sep;80(9):2806-14 [7673428.001]
  • [Cites] Science. 1973 Jan 5;179(4068):77-9 [4682131.001]
  • [Cites] Dig Liver Dis. 2004 Feb;36 Suppl 1:S68-77 [15077914.001]
  • [Cites] J Cell Biochem. 2003 Dec 1;90(5):1026-37 [14624462.001]
  • [Cites] Biochim Biophys Acta. 2003 Sep 22;1616(1):1-84 [14507421.001]
  • [Cites] Gene. 2003 Mar 13;306:1-12 [12657462.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 27;331(1):1-14 [15845350.001]
  • (PMID = 19365586.001).
  • [ISSN] 1687-6369
  • [Journal-full-title] Advances in urology
  • [ISO-abbreviation] Adv Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2667939
  •  go-up   go-down


13. Kizawa K, Toyoda M, Ito M, Morohashi M: Aberrantly differentiated cells in benign pilomatrixoma reflect the normal hair follicle: immunohistochemical analysis of Ca-binding S100A2, S100A3 and S100A6 proteins. Br J Dermatol; 2005 Feb;152(2):314-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrantly differentiated cells in benign pilomatrixoma reflect the normal hair follicle: immunohistochemical analysis of Ca-binding S100A2, S100A3 and S100A6 proteins.
  • BACKGROUND: Pilomatrixoma is a common benign cutaneous tumour containing differentiated hair matrix cells.
  • This tumour is mainly composed of basophilic, transitional, shadow and squamoid cells.
  • OBJECTIVES: To characterize the disordered epithelial elements of pilomatrixoma by localizing S100A2, S100A3 and S100A6 proteins.
  • RESULTS: Tissue-specific distribution of the S100 proteins investigated was preserved in the morphologically disordered tumour tissues.
  • CONCLUSIONS: The epithelial elements of pilomatrixoma can be characterized using S100 proteins as biochemical markers.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Hair Diseases / metabolism. Pilomatrixoma / metabolism. S100 Proteins / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Basophils / metabolism. Calcium-Binding Proteins / metabolism. Cell Cycle Proteins / metabolism. Cell Differentiation. Chemotactic Factors / metabolism. Hair Follicle / metabolism. Humans. Neoplasm Proteins / metabolism. Skin / metabolism

  • Genetic Alliance. consumer health - Pilomatrixoma.
  • MedlinePlus Health Information. consumer health - Hair Problems.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15727645.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Cell Cycle Proteins; 0 / Chemotactic Factors; 0 / Neoplasm Proteins; 0 / S100 Proteins; 0 / S100A2 protein, human; 0 / S100A3 protein, human; 105504-00-5 / S100A6 protein, human
  •  go-up   go-down


14. Mahmoud A, Hill DH, O'Sullivan MJ, Bennett MW: Cylindroma of the breast: a case report and review of the literature. Diagn Pathol; 2009;4:30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cylindroma of the breast is a very rare lesion which is morphological and immunophenotypically identical to benign dermal cylindroma.
  • The patient had no significant family or past medical history, and specifically no history of breast or skin diseases.
  • The tumor consisted of well circumscribed islands of epithelial cells surrounded by a dense membrane material, and focally containing hyaline globules.
  • At low power the islands of tumour cells formed a "jig-saw" pattern, which is typical of cylindroma, but was present within normal breast parenchyma and no had direct connection with the overlying skin.
  • Immunohistochemistry for ER, PR, and Her2/neu was negative in tumour cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19725978.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3224926
  •  go-up   go-down


15. Shilo K, Miettinen M, Travis WD, Timens W, Nogueira R, Franks TJ: Pulmonary microcystic fibromyxoma: Report of 3 cases. Am J Surg Pathol; 2006 Nov;30(11):1432-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three cases of pulmonary myxoid tumors showing a variable degree of microcystic change are described.
  • The tumors ranged in size from 1 to 2.3 cm (mean 1.4 cm).
  • Innocuous, widely-spaced, spindled to stellate tumor cells showed minimal nuclear pleomorphism and absence of mitotic activity.
  • No epithelial, chondroid, neural, myofibroblastic, lipomatous or vascular differentiation was evident on immunohistochemical studies.
  • Although these cases display cytologic features, myxoid stroma and benign clinical course characteristic of pulmonary myxomas; the presence of microcystic architecture is unique to the current series, and thus a descriptive designation "microcystic fibromyxoma" is suggested.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17063085.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Chou SH, Tseleni-Balafouta S, Moon HS, Chamberland JP, Liu X, Kavantzas N, Mantzoros CS: Adiponectin receptor expression in human malignant tissues. Horm Cancer; 2010 Jun;1(3):136-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used immunohistochemistry to assess expression of adiponectin receptors in archival specimens of renal cell carcinoma (n = 64), hepatocellular carcinoma (n = 123), melanoma (n = 20), cholangiocarcinoma (n = 20), transitional cell carcinoma of the bladder (n = 24), ovarian epithelial carcinoma (n = 63), cervical squamous cell carcinoma (n = 49), and adrenocortical carcinoma (n = 48).
  • There was no difference in the expression of adiponectin receptors or their mRNA between malignant and benign kidney tissue specimens.
  • Overall, there were no correlations between expression of adiponectin receptors or their mRNA and tumor prognostic factors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Nutr. 2007 Sep;86(3):s858-66 [18265479.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):993-7 [12629074.001]
  • [Cites] Int J Colorectal Dis. 2009 Mar;24(3):275-81 [18979105.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81 [14983034.001]
  • [Cites] Oncology. 2007;73(3-4):261-9 [18424891.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83 [10092513.001]
  • [Cites] Int J Oncol. 2009 Feb;34(2):339-44 [19148467.001]
  • [Cites] Dig Dis Sci. 2008 Mar;53(3):597-605 [17763959.001]
  • [Cites] Cancer Lett. 2010 Feb 28;288(2):177-82 [19646806.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Endocrinology. 2010 Jan;151(1):115-22 [19887569.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94 [16288122.001]
  • [Cites] Jpn J Clin Oncol. 2008 Feb;38(2):106-11 [18245516.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 22;333(1):79-87 [15936715.001]
  • [Cites] Breast Cancer Res Treat. 2008 Dec;112(3):405-10 [18163210.001]
  • [Cites] Maturitas. 2009 Jul 20;63(3):253-6 [19524379.001]
  • [Cites] Int J Cancer. 1993 Oct 21;55(4):555-61 [8406981.001]
  • [Cites] Clin Sci (Lond). 2002 Aug;103(2):137-42 [12149104.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):395-403 [12884914.001]
  • [Cites] Mol Cell Endocrinol. 2008 Mar 26;285(1-2):43-50 [18313838.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5 [11572954.001]
  • [Cites] Obstet Gynecol Surv. 2005 Oct;60(10):683-92 [16186785.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6365-78 [15322511.001]
  • [Cites] Obesity (Silver Spring). 2006 Jan;14(1):28-35 [16493120.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):1041-8 [17192291.001]
  • [Cites] Trends Pharmacol Sci. 2005 Feb;26(2):69-76 [15681023.001]
  • [Cites] Lancet. 2008 Feb 16;371(9612):569-78 [18280327.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1430-6 [17512191.001]
  • [Cites] Oncol Rep. 2008 Oct;20(4):971-7 [18813842.001]
  • [Cites] J Biol Chem. 2005 May 6;280(18):18341-7 [15734737.001]
  • [Cites] Int J Hematol. 2008 Nov;88(4):374-80 [18818986.001]
  • [Cites] J Clin Pathol. 2009 Aug;62(8):705-9 [19638541.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):140-6 [17036323.001]
  • [Cites] Endocr Relat Cancer. 2008 Mar;15(1):289-99 [18310295.001]
  • [Cites] BMJ. 2007 Dec 1;335(7630):1134 [17986716.001]
  • [Cites] Eur Urol. 2008 Oct;54(4):866-73 [18343565.001]
  • [Cites] Int J Obes (Lond). 2007 Dec;31(12):1843-8 [17607322.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1573-8 [17205522.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1160-3 [15001602.001]
  • [Cites] Anticancer Res. 2009 Aug;29(8):3321-7 [19661351.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):432-6 [8621222.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):814-21 [12910527.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Gut. 2008 Nov;57(11):1531-8 [18676419.001]
  • [Cites] Lung Cancer. 2008 Sep;61(3):391-7 [18342391.001]
  • [Cites] Cancer Causes Control. 2009 Jul;20(5):625-33 [19051043.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):901-9 [16841257.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):308-13 [17301264.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1214-21 [18483344.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1120-7 [17459059.001]
  • (PMID = 21761356.001).
  • [ISSN] 1868-8500
  • [Journal-full-title] Hormones & cancer
  • [ISO-abbreviation] Horm Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Adiponectin
  •  go-up   go-down


17. Abrahão AC, Camisasca DR, Bonelli BR, Cabral MG, Lourenço SQ, Torres SR, Pinto DS Jr: Recurrent bilateral gingival peripheral calcifying epithelial odontogenic tumor (Pindborg tumor): a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep;108(3):e66-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent bilateral gingival peripheral calcifying epithelial odontogenic tumor (Pindborg tumor): a case report.
  • Calcifying epithelial odontogenic tumor (CEOT) is an extremely rare, benign neoplasm, accounting for approximately 1% of all odontogenic tumors.
  • Morphologic features, and histochemical and immunohistochemical tests revealed bilateral peripheral calcifying odontogenic epithelial tumor.
  • [MeSH-major] Gingival Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Odontogenic Tumors / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Follow-Up Studies. Gingival Diseases / diagnosis. Granuloma, Pyogenic / diagnosis. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716494.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Pawlicki J, Król R, Kajor M, Ziaja J: [Case of malignant tumour phyllodes converting to fibrosarcoma]. Pol Merkur Lekarski; 2007 Mar;22(129):215-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of malignant tumour phyllodes converting to fibrosarcoma].
  • Tumour phyllodes is rare breast neoplasm.
  • Tumours phyllodes are composed of hypercellular mesenchymal stroma and epithelial elements.
  • They are commonly classified as benign, rarely as borderline or malignant.
  • There is a case of large (28 x 24 cm) malignant tumour phyllodes presented in the article.
  • After surgical treatment of recurrent tumours (fibrosarcoma form) occurred two times during 1 year time.
  • In spite of unfavorable prognostic features of the tumour (large size, malignant histological character) and recurrences, final therapeutic effect was good.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Fibrosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Phyllodes Tumor / pathology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682679.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


19. Behzatoğlu K, Durak H, Canberk S, Aydin O, Huq GE, Oznur M, Ozyalvaçli G, Yildiz P: Giant cell tumor-like lesion of the urinary bladder: a report of two cases and literature review; giant cell tumor or undifferentiated carcinoma? Diagn Pathol; 2009;4:48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor-like lesion of the urinary bladder: a report of two cases and literature review; giant cell tumor or undifferentiated carcinoma?
  • Giant cell tumor, excluding its prototype in bone, is usually a benign but local aggressive neoplasm originating from tendon sheath or soft tissue.
  • Giant cell tumors in visceral organs usually accompany epithelial tumors and the clinical behavior of giant cell tumor in urinary bladder is similar to its bone counterpart.
  • Here, we report two cases of giant cell tumor located in urinary bladder in comparison with nine reported cases in the English literature.
  • One of the two cases we present had no concurrent urothelial tumor at the time of diagnosis but had a history of a low grade noninvasive urothelial carcinoma with three recurrences.
  • The histology of these two cases was similar to the giant cell tumor of bone and composed of oval to spindle mononuclear cells with evenly spaced osteoclast-like giant cells.
  • The histologic and immunohistochemical properties in our cases as well as their clinical courses were consistent with a giant cell tumor.
  • Consequently, tumors in urinary bladder showing features of giant cell tumor of bone may also be considered and termed "giant cell tumor".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] J Urol. 2002 Apr;167(4):1784 [11912413.001]
  • [Cites] J Orthop Sci. 2005 Nov;10(6):581-8 [16307183.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):161-71 [16322750.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):495-500 [16625096.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Feb;264(2):205-8 [16977452.001]
  • [Cites] Mod Pathol. 2001 Dec;14(12):1209-15 [11743042.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1467-76 [12409723.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):450-6 [12828610.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):440-3 [15043462.001]
  • [Cites] BMC Urol. 2004 Jun 18;4:7 [15207006.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):953-61 [15223968.001]
  • [Cites] Cancer. 1973 Mar;31(3):621-5 [4693590.001]
  • [Cites] Am J Clin Pathol. 1984 May;81(5):666-75 [6326564.001]
  • [Cites] J Urol. 1985 Mar;133(3):472-5 [3974000.001]
  • [Cites] J Urol. 1989 Jul;142(1):120-2 [2733086.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):43-8 [2432851.001]
  • [Cites] Am J Surg Pathol. 1991 Feb;15(2):160-8 [1989464.001]
  • [Cites] Histopathology. 1990 Nov;17(5):413-8 [1706298.001]
  • [Cites] J Oral Pathol Med. 1999 Feb;28(2):54-8 [9950250.001]
  • (PMID = 20043822.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2811699
  •  go-up   go-down


20. Peng Y, Chen F, Melamed J, Chiriboga L, Wei J, Kong X, McLeod M, Li Y, Li CX, Feng A, Garabedian MJ, Wang Z, Roeder RG, Lee P: Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci U S A; 2008 Apr 1;105(13):5236-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently identified p44/MEP50 as an AR coactivator and further showed that it is expressed primarily in the nucleus and cytoplasm of benign prostate epithelial and prostate cancer cells, respectively.
  • We also showed that haploinsufficiency in p44(+/-) mice causes prostate epithelial cell proliferation.
  • To establish direct cause-and-effect relationships, we have used p44 fusion proteins that are selectively expressed in the nucleus or cytoplasm of prostate cancer cells (LNCaP), along with RNAi analyses, to examine effects of p44 both in vitro and in vivo (in tumor xenografts).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1999 Sep 3;98(5):675-86 [10490106.001]
  • [Cites] J Mol Endocrinol. 2006 Oct;37(2):283-300 [17032745.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11345-53 [16357141.001]
  • [Cites] J Mol Endocrinol. 2006 Jun;36(3):463-83 [16720717.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1891-5 [10815912.001]
  • [Cites] Biochem Soc Trans. 2000;28(4):415-8 [10961931.001]
  • [Cites] Cell Growth Differ. 2002 Jan;13(1):1-11 [11801526.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):736-48 [11847121.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):7076-85 [11751884.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):8243-7 [11756452.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):207-23 [12085963.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1467-74 [12368219.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2002;12(3):193-207 [12449343.001]
  • [Cites] Essays Biochem. 2000;36:89-103 [12471905.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 1;31(3):999-1005 [12560496.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):7019-29 [12972618.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13944-52 [14711828.001]
  • [Cites] Science. 1988 May 13;240(4854):889-95 [3283939.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1304-11 [8443809.001]
  • [Cites] Prostate. 1993;22(2):109-18 [7681204.001]
  • [Cites] Curr Opin Genet Dev. 1999 Apr;9(2):140-7 [10322133.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jul 7;345(3):1051-8 [16712789.001]
  • [Cites] J Cell Biochem. 2006 Oct 1;99(2):333-44 [16518832.001]
  • [Cites] EMBO Rep. 2005 Jan;6(1):70-6 [15592453.001]
  • (PMID = 18356297.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK058024; United States / NIDDK NIH HHS / DK / DK071900; United States / NCRR NIH HHS / RR / UL1 RR025741; United States / NIDDK NIH HHS / DK / R01 DK071900; United States / NIDDK NIH HHS / DK / R01 DK065156; United States / NIDDK NIH HHS / DK / R01 DK058024; United States / NIDDK NIH HHS / DK / DK065156 01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / Receptors, Androgen; 0 / Transcription Factors; 0 / p44 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6
  • [Other-IDs] NLM/ PMC2278178
  •  go-up   go-down


21. Agoston AT, Liang CW, Richkind KE, Fletcher JA, Vargas SO: Trisomy 18 is a consistent cytogenetic feature in pilomatricoma. Mod Pathol; 2010 Aug;23(8):1147-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilomatricoma, also known as 'calcifying epithelioma of Malherbe', is a common skin adnexal tumor that mimics hair growth.
  • This aberration was corroborated by interphase fluorescence in situ hybridization, using a chromosome 18 pericentromeric probe, in the basaloid epithelial component of 7 of 11 pilomatricomas, including the index case.
  • Trisomy 18 was present in a small subset of cells, suggesting a role in pilomatricoma progression, rather than in tumor initiation.
  • We conclude that trisomy 18 is a consistent feature in pilomatricoma, suggesting that genes carried on this chromosome, such as that for the antiapoptotic oncoprotein BCL2, may have a role in the growth and differentiation of this benign self-limited tumor.
  • [MeSH-major] Chromosomes, Human, Pair 18. Hair Diseases / genetics. Pilomatrixoma / genetics. Skin Neoplasms / genetics. Trisomy

  • Genetic Alliance. consumer health - Trisomy 18.
  • MedlinePlus Health Information. consumer health - Hair Problems.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495544.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Streitz JM Jr, Madden MT, Marimanikkuppam SS, Krick TP, Salo WL, Aufderheide AC: Analysis of protein expression patterns in Barrett's esophagus using MALDI mass spectrometry, in search of malignancy biomarkers. Dis Esophagus; 2005;18(3):170-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We postulate that direct analysis of epithelial proteins using mass spectrometry will provide protein profiles capable of identifying patients at high risk of developing malignancy.
  • Our aim is to find transitional protein signals that show a cancer profile within histologically benign BE, which can be used as indicators of early malignant change.
  • Samples of squamous epithelium, and both benign and malignant Barrett's epithelium, were compared for differences in protein expression.
  • Reliable differentiation of squamous and Barrett's epithelium was demonstrated.
  • A comparison of benign and malignant Barrett's epithelium identified a number of cancer-specific protein peaks that were deletion or expression variations from benign epithelium.
  • In four instances the proteins (7350, 8446, 10850, and 14693) appeared to be early malignant changes in histologically benign BE.
  • Mass spectrometry performed upon fresh-frozen Barrett's epithelium, obtained by laser-capture microdissection, displays reproducible, tissue-specific, protein profiles.
  • Distinct differences are demonstrated between benign and malignant epithelium, some of which appear to be candidate biomarkers of early malignant change.
  • This technique reliably displays cellular protein expression in esophageal epithelium and deserves further study as a tool to identify early malignant degeneration in BE.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045579.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Lehrer S, Stone NN, Stock RG: Prostate cancer in a large prostate is associated with a decreased prostate specific antigen failure rate after brachytherapy. J Urol; 2005 Jan;173(1):79-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Some investigators have postulated that paracrine signals acting to regulate epithelial proliferation in benign prostatic hypertrophy have beneficial influences on coexistent prostate cancer.
  • Moreover, since we found that prostate size is independent of PSA, Gleason score and tumor stage for predicting outcome, we hypothesize that patients with a small prostate treated with brachytherapy might benefit from hormone treatment and larger radiation doses.
  • These measures are now generally reserved for men with more advanced tumors, higher PSA and increased Gleason scores.


24. Huang W, Kanehira K, Drew S, Pier T: Oncocytoma can be differentiated from its renal cell carcinoma mimics by a panel of markers: an automated tissue microarray study. Appl Immunohistochem Mol Morphol; 2009 Jan;17(1):12-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study presents a panel of markers that are readily available, easy to use, and useful for differential diagnoses of renal tumors.
  • DESIGN: A renal cell neoplasm tissue microarray was constructed including oncocytoma (n=30), chromophobe RCC (n=18), conventional RCC (n=64), papillary RCC (n=50), and benign renal tissues (n=31).
  • CK7, CD10, epithelial membrane antigen, renal cell carcinoma marker (RCCma), vimentin, and endogenous avidin-binding activity (EABA) were studied.

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769342.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Vimentin; EC 2.7.11.22 / MOK protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


25. Zafrakas M, Chorovicer M, Klaman I, Kristiansen G, Wild PJ, Heindrichs U, Knüchel R, Dahl E: Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue. Int J Cancer; 2006 Mar 15;118(6):1453-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GABRP downregulation in breast cancer was confirmed by quantitative RT-PCR in cryopreserved breast tumour and normal breast tissue specimens (n = 22), in archival formalin-fixed, paraffin-embedded tissue specimens (n = 32), as well as in breast cancer cell lines (n = 8).
  • Furthermore, a significant downregulation of GABRP was noted in large (pT3-pT4) (p = 0.044) primary breast tumours.
  • Non-radioisotopic ISH showed strong GABRP expression in normal epithelial and benign papilloma breast cells, but no signal could be detected in invasive ductal carcinoma.
  • Altogether, these data suggest that GABRP is progressively down-regulated with tumour-progression, and that it may be useful as a prognostic marker in breast cancer.
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization / methods. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction


26. Zhang YF, Wang HN, Hong TP: [Ghrelin expression in the tissues of different thyroid diseases]. Beijing Da Xue Xue Bao; 2006 Apr 18;38(2):193-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ghrelin expression in the tissues of different thyroid diseases].
  • OBJECTIVE: To investigate whether ghrelin, a novel endogenous ligand of growth hormone secretagogue receptor (GHS-R), was expressed in the thyroid tissues of different thyroid diseases, and its implication.
  • METHODS: The paraffin-embedded specimens of thyroid tissues from 2000 to 2004 were obtained from 57 patients with different thyroid diseases, including 5 subacute thyroiditis, 8 Hashimoto's thyroiditis, 7 hyperthyroidism (Graves disease), 8 nodular goiter, 5 thyroid adenoma, 3 thyroid lymphoma, 8 papillary carcinoma, 3 follicular carcinoma, 5 medullary carcinoma and 5 undifferentiated carcinoma cases.
  • (1) ghrelin expression was undetectable in the thyroid tissues of normal control, subacute thyroiditis, Hashimoto's thyroiditis and Graves disease. (2) ghrelin expression was also undetected in the tissues of nodular goiter, thyroid adenoma and thyroid lymphoma. (3) ghrelin-positive staining was found in the tumor cells of different types of thyroid carcinoma.
  • CONCLUSION: Ghrelin is expressed in malignant epithelial thyroid neoplasms, but not in autoimmune or inflammatory thyroid diseases and benign nodular thyroid diseases.
  • [MeSH-major] Ghrelin / metabolism. Thyroid Diseases / metabolism. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617365.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ghrelin
  •  go-up   go-down


27. Zeng Y, Kakehi Y, Nouh MA, Tsunemori H, Sugimoto M, Wu XX: Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia. Prostate; 2009 Feb 15;69(3):283-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia.
  • OBJECTIVE: To elucidate gene expression profiles of lysophosphatidic acid (LPA)-related molecules in cancer, pre-cancerous lesion, and benign hyperplasia of the prostate.
  • Cancer cells and the corresponding stromal cells from normal prostate, high grade intraepithelial neoplasia (HGPIN), benign hyperplastic glands were isolated by laser capture microdissection. mRNA levels of three LPA receptors, LPA1, LPA2, LPA3, two LPA-synthesizing enzymes, autotaxin (ATX), acylglycerol kinase (AGK), and a LPA-degradation enzyme, prostatic acid phosphatase (PAP), were quantitatively assessed.
  • RESULTS: LPA1 mRNA level was significantly decreased in HGPIN and cancer epithelia when compared to the benign glands.
  • LPA3 mRNA level was elevated in cancer epithelia compared to benign glands.
  • In BPH, AGK was abundantly expressed in the stroma while PAP was predominant in epithelial cells.
  • LPA may also play a key role in the development of benign prostatic hyperplasia.
  • [MeSH-minor] Aged. Aged, 80 and over. Androgens / metabolism. Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Humans. Lectins, C-Type / genetics. Lectins, C-Type / metabolism. Lysophospholipids / metabolism. Male. Microdissection. Middle Aged. Multienzyme Complexes / genetics. Multienzyme Complexes / metabolism. Phosphodiesterase I / genetics. Phosphodiesterase I / metabolism. Phosphoric Diester Hydrolases. Phosphotransferases (Alcohol Group Acceptor) / genetics. Phosphotransferases (Alcohol Group Acceptor) / metabolism. Prostate / physiology. Pyrophosphatases / genetics. Pyrophosphatases / metabolism. RNA, Messenger / metabolism. Urinary Bladder Neoplasms / genetics. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19025891.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / Lysophospholipids; 0 / Multienzyme Complexes; 0 / RNA, Messenger; 0 / Receptors, Lysophosphatidic Acid; 0 / pancreatitis-associated protein; 22002-87-5 / lysophosphatidic acid; EC 2.7.1.- / AGK protein, human; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 3.1.4.- / Phosphoric Diester Hydrolases; EC 3.1.4.1 / Phosphodiesterase I; EC 3.1.4.39 / alkylglycerophosphoethanolamine phosphodiesterase; EC 3.6.1.- / Pyrophosphatases
  •  go-up   go-down


28. Haass NK, Wladykowski E, Kief S, Moll I, Brandner JM: Differential induction of connexins 26 and 30 in skin tumors and their adjacent epidermis. J Histochem Cytochem; 2006 Feb;54(2):171-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential induction of connexins 26 and 30 in skin tumors and their adjacent epidermis.
  • Gap junctions (GJs) have been shown to play a role in tumor progression including a variety of keratinocyte-derived and non-keratinocyte-derived skin tumors.
  • Here we show that the synthesis of the GJ proteins connexin 26 and connexin 30 (Cx26 and Cx30) is induced in keratinocyte-derived epithelial skin tumors whereas there is either no change or a downregulation of Cx43.
  • Cx26, Cx30, and Cx43 are absent in non-epithelial skin tumors.
  • Further, Cx26 and Cx30 are induced in the epidermis adjacent to malignant melanoma but absent in the epidermis adjacent to benign non-epithelial skin lesions (melanocytic nevi and angioma).
  • The keratinocyte-derived skin tumors are very heterogeneous regarding the Cx26/Cx30 pattern in the epidermis at the periphery of the tumors.
  • We further discuss the putative roles of these gap junctional proteins in tumor progression.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046668.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Connexins; 0 / GJB6 protein, human; 127120-53-0 / connexin 26; 68238-35-7 / Keratins
  •  go-up   go-down


29. Perrone G, Vincenzi B, Zagami M, Santini D, Panteri R, Flammia G, Verzì A, Lepanto D, Morini S, Russo A, Bazan V, Tomasino RM, Morello V, Tonini G, Rabitti C: Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade. Mod Pathol; 2007 Mar;20(3):344-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade.
  • Stromal tissues, normal epithelial cells and prostate intraepithelial neoplasia (PIN) of any grade around and distant from cancer were always negative for reelin.
  • Reelin was found in malignant prostatic epithelial glands of 50% cases Gleason score 10, 52% Gleason score 9, 56% Gleason score 8, 18% Gleason score 7, while no sample of prostate cancers with Gleason score 6 showed reelin expression (P=0,005).
  • Our results demonstrated for the first time that reelin is expressed in prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly with increasing of single Gleason patterns.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cell Adhesion Molecules, Neuronal / biosynthesis. Extracellular Matrix Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Serine Endopeptidases / biosynthesis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277764.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules, Neuronal; 0 / Extracellular Matrix Proteins; 0 / Nerve Tissue Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / reelin protein
  •  go-up   go-down


30. Münz M, Zeidler R, Gires O: The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Cancer Lett; 2005 Jul 8;225(1):151-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP.
  • The epithelial cell adhesion molecule, EpCAM, is a transmembrane glycoprotein associated with both benign and malignant proliferation.
  • In cancer cells, expression levels of this tumour-associated antigen correlate positively with the grade of dysplasia and are also a negative prognostic factor for breast cancer patients.
  • De novo expression of EpCAM resulted in the rapid upregulation of the proto-oncogene c-Myc along with enhanced cell proliferation and metabolism.
  • Here, we analyzed the effects of EpCAM onto the proteome of epithelial cells.
  • Taken together, these results provide further evidence for the direct involvement of EpCAM in signalling processes, gene regulation, and cellular metabolism supporting its important role in tumour biology.
  • [MeSH-major] Antigens, Neoplasm / physiology. Carcinoma, Squamous Cell / genetics. Cell Adhesion Molecules / physiology. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Antigens, Differentiation. Carrier Proteins. Cell Proliferation. Epithelial Cells. Fatty Acid-Binding Proteins. Fatty Acids. Genes, myc. Humans. Proteome. Signal Transduction. Tumor Cells, Cultured. Up-Regulation

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922867.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Antigens, Neoplasm; 0 / Carrier Proteins; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / FABP5 protein, human; 0 / Fatty Acid-Binding Proteins; 0 / Fatty Acids; 0 / Proteome
  •  go-up   go-down


31. Nistal M, García-Cabezas MA, Castello MC, De Miguel MP, Regadera J: Age-related epididymis-like intratesticular structures: benign lesions of Wolffian origin that can be misdiagnosed as testicular tumors. J Androl; 2006 Jan-Feb;27(1):79-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-related epididymis-like intratesticular structures: benign lesions of Wolffian origin that can be misdiagnosed as testicular tumors.
  • The lesion is characterized by a pseudostratified cylindrical epithelium, with a robust pankeratin and 8, 18, and 19 keratin expression, focal vimentin expression, and apical CD 10 expression, similar to what is proper of the normal human epididymidis.
  • The epithelial layer of ELITSs was surrounded by a thin layer of smooth-muscle cells.
  • The ELITSs are distinct from atrophic seminiferous tubules with a Sertoli cell-only pattern and from the benign glandular teratomatous component of an involution of a malignant testicular germ cell tumor, the so-called burn-out germ cell tumor.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400082.001).
  • [ISSN] 0196-3635
  • [Journal-full-title] Journal of andrology
  • [ISO-abbreviation] J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Kross KW, Heimdal JH, Olsnes C, Olofsson J, Aarstad HJ: Head and neck squamous cell carcinoma spheroid- and monocyte spheroid-stimulated IL-6 and monocyte chemotactic protein-1 secretion are related to TNM stage, inflammatory state and tumor macrophage density. Acta Otolaryngol; 2005 Oct;125(10):1097-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck squamous cell carcinoma spheroid- and monocyte spheroid-stimulated IL-6 and monocyte chemotactic protein-1 secretion are related to TNM stage, inflammatory state and tumor macrophage density.
  • The aim of this investigation was to study this cytokine secretion in relation to other cytokines, spheroid composition and host factors.In series I (n=14) the densities of epithelial cells, fibroblasts and macrophages were determined in sections from F-spheroids and donor tissue.
  • In series II (n=17) the TNM stage, donor inflammatory state, macrophage density and the secretion of F-spheroid- and monocyte F-spheroid-stimulated IL-6, MCP-1 and tumor necrosis factor (TNF)-alpha were determined.
  • Epithelial cells were partly replaced by interstitial tissue during spheroid formation.
  • Malignant (M) F-spheroids secreted more MCP-1 than benign (B) F-spheroids.
  • [MeSH-minor] Blood Sedimentation. Cell Count. Coculture Techniques. Humans. Macrophages. Neoplasm Staging. Tumor Cells, Cultured. Tumor Necrosis Factor-alpha / secretion


33. Mosnier JF, Kandel C, Cazals-Hatem D, Bou-Hanna C, Gournay J, Jarry A, Laboisse CL: N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mod Pathol; 2009 Feb;22(2):182-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a definite immunoprofile of this tumor is missing, the histopathologic diagnosis of intrahepatic cholangiocarcinoma is difficult.
  • The aim of this study was to explore E- and N-cadherin expressions in intrahepatic bile duct tumors, and to determine their potential interest in differential diagnosis.
  • In normal liver, epithelial cells of intrahepatic bile ducts, whatever their caliber, as well as hepatocytes, coexpressed E- and N-cadherins at their plasma membranes.
  • All the benign lesions and 30 of the 45 intrahepatic cholangiocarcinomas (23/29 peripheral and 7/16 hilar) also expressed N-cadherin.
  • The expression of N-cadherin at the plasma membrane of tumor cells was significantly more frequent in peripheral than in hilar intrahepatic cholangiocarcinomas (P=0.003).
  • Among noncholangiocarcinomas, only 1% gastric and 66% gallbladder adenocarcinomas and all the hepatocellular carcinomas expressed N-cadherin at the membrane of tumor cells.
  • Finally, for the diagnosis of intrahepatic cholangiocarcinomas, the specificity value of membranous expression of N-cadherin was 88%, whereas that of the combination cytokeratin 7/membranous N-cadherin was 98%.
  • In combination with cytokeratin 7 and Hep Par1, N-cadherin is a reliable tool for the histopathological diagnosis of primary hepatic tumors.
  • [MeSH-major] Antigens, CD / analysis. Bile Duct Neoplasms / immunology. Bile Ducts, Intrahepatic / immunology. Biomarkers, Tumor / analysis. Cadherins / analysis. Cholangiocarcinoma / immunology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622386.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CDH1 protein, human; 0 / CDH2 protein, human; 0 / Cadherins; 0 / KRT7 protein, human; 0 / Keratin-7
  •  go-up   go-down


34. Kimura S, Naganuma S, Susuki D, Hirono Y, Yamaguchi A, Fujieda S, Sano K, Itoh H: Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncol Rep; 2010 Jun;23(6):1625-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microarray analysis showed up-regulation of miR-21, miR-16 and miR-30a-5p in HNSCC and ESCC cell lines compared to normal squamous epithelial cell lines, and consistent high expression of miR-205 and let-7a in both normal and malignant squamous epithelial cell lines.
  • Validation study using real-time quantitative RT-PCR in formalin-fixed paraffin-embedded cancer tissues and paired normal epithelia obtained by Laser-captured microdissection revealed that miR-205 showed highest expression in both malignant and benign squamous epithelia, although it was less expressed in cell lines and tissues other than squamous epithelia.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. Esophageal Neoplasms / genetics. Head and Neck Neoplasms / genetics. MicroRNAs / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428818.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN205 microRNA, human; 0 / MIRN21 microRNA, human; 0 / MicroRNAs; 0 / RNA, Messenger
  •  go-up   go-down


35. Nabarra B, Pontoux C, Godard C, Osborne-Pellegrin M, Ezine S: Neoplastic transformation and angiogenesis in the thymus of transgenic mice expressing SV40 T and t antigen under an L-pyruvate kinase promoter (SV12 mice). Int J Exp Pathol; 2005 Dec;86(6):397-413
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using several techniques, we have assessed morphological characteristics of a malignant thymic tumour in SV12 transgenic (Tg) mice expressing SV40 T and t antigens under control of an L-PK promoter.
  • We describe the development of a carcinoma originating from thymic hyperplasia and followed by the formation of a benign tumour composed chiefly of medullary epithelial cells expressing the transgene and of lymphocytes, a pathology very rarely reported in mice.
  • Our study of the SV12 Tg mice represents the first description of a model of a pure malignant thymic tumour associated with extensive angiogenesis maintained in numerous descendants.
  • The formation of a large tumoral neovascular network, observed here, has never been described in human and/or experimental thymic tumours.
  • The subset of different molecular weight CK components and their modifications are also considered, as well as the presence of type IV epithelial cells, progenitors of medullary epithelial cells.
  • [MeSH-major] Antigens, Polyomavirus Transforming / genetics. Antigens, Viral, Tumor / genetics. Neovascularization, Pathologic. Promoter Regions, Genetic. Pyruvate Kinase / genetics. Thymus Neoplasms / pathology
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Female. Immunohistochemistry / methods. Male. Mice. Mice, Inbred CBA. Mice, Transgenic. Microscopy, Immunoelectron. Thymus Gland / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thymus. 1993 Aug;22(1):13-33 [7508157.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):409-16 [8123467.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2686-98 [8139568.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3979-83 [8171023.001]
  • [Cites] Prog Growth Factor Res. 1994;5(1):89-97 [7515293.001]
  • [Cites] Histopathology. 1994 Jul;25(1):21-9 [7959642.001]
  • [Cites] Int Rev Cytol. 1995;159:113-60 [7537724.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1029-39 [7538264.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):127-37 [8534862.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] J Pathol. 1995 Nov;177(3):309-15 [8551394.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5742-6 [8650163.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cancer Metastasis Rev. 1995 Dec;14(4):263-77 [8821090.001]
  • [Cites] Cancer Lett. 1996 Oct 22;107(2):293-300 [8947527.001]
  • [Cites] Cell. 1997 Jun 13;89(6):981-90 [9200616.001]
  • [Cites] Science. 1997 Jul 4;277(5322):48-50 [9229772.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] Lab Invest. 1990 Jun;62(6):690-6 [1694254.001]
  • [Cites] Lab Invest. 1990 Sep;63(3):298-306 [1697637.001]
  • [Cites] Anticancer Res. 1990 Sep-Oct;10(5A):1335-9 [1700664.001]
  • [Cites] Annu Rev Physiol. 1991;53:217-39 [1710435.001]
  • [Cites] Exp Pathol. 1990;40(4):301-12 [2098275.001]
  • [Cites] Eur J Cancer. 1991;27(6):781-5 [1712608.001]
  • [Cites] Virchows Arch. 1998 Jan;432(1):33-42 [9463585.001]
  • [Cites] Nat Med. 2000 Apr;6(4):389-95 [10742145.001]
  • [Cites] Dev Comp Immunol. 2001 Apr;25(3):231-43 [11164888.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):635-42 [12068292.001]
  • [Cites] Immunity. 2002 Jun;16(6):803-14 [12121662.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):2842-5 [12218095.001]
  • [Cites] Mol Aspects Med. 2002 Dec;23(6S):S1-27 [12537983.001]
  • [Cites] Dev Immunol. 2002 Dec;9(4):223-31 [15144019.001]
  • [Cites] Cancer Res. 1975 Oct;35(10):2771-9 [1157049.001]
  • [Cites] Nature. 1979 Mar 15;278(5701):261-3 [218111.001]
  • [Cites] J Mol Biol. 1981 Dec 25;153(4):933-59 [6177862.001]
  • [Cites] Am J Clin Pathol. 1982 Oct;78(4):500-7 [6182789.001]
  • [Cites] Cell. 1982 Sep;30(2):361-72 [6183000.001]
  • [Cites] Differentiation. 1983;23(3):256-69 [6189757.001]
  • [Cites] Pathol Res Pract. 1982;175(2-3):256-65 [6190148.001]
  • [Cites] Am J Pathol. 1984 Jan;114(1):121-30 [6197886.001]
  • [Cites] J Pathol. 1983 Nov;141(3):385-413 [6198502.001]
  • [Cites] Lab Invest. 1984 Jan;50(1):36-41 [6198559.001]
  • [Cites] Cell. 1984 Jun;37(2):367-79 [6327063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11822-7 [9751749.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1474-81 [9850173.001]
  • [Cites] Semin Diagn Pathol. 1999 Feb;16(1):2-17 [10355650.001]
  • [Cites] Pathology. 1998 May;30(2):111-22 [9643488.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7533-7 [8356051.001]
  • [Cites] Cancer Res. 1984 Dec;44(12 Pt 1):5797-804 [6209004.001]
  • [Cites] Lab Invest. 1985 Jan;52(1):31-8 [2578201.001]
  • [Cites] Lab Invest. 1985 Mar;52(3):243-56 [2579289.001]
  • [Cites] Mol Cell Biol. 1985 Apr;5(4):642-8 [2985963.001]
  • [Cites] J Natl Cancer Inst. 1985 Aug;75(2):369-79 [3860689.001]
  • [Cites] Nature. 1985 Aug 1-7;316(6027):457-60 [2991771.001]
  • [Cites] Lab Invest. 1986 Nov;55(5):521-30 [2430138.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] J Virol. 1987 Jun;61(6):2029-32 [3033329.001]
  • [Cites] Thymus. 1987;9(2):95-121 [3296336.001]
  • [Cites] Mol Cell Biol. 1987 Sep;7(9):3178-84 [3118193.001]
  • [Cites] EMBO J. 1987 Sep;6(9):2699-704 [2824189.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 May;85(9):3135-9 [2452444.001]
  • [Cites] J Comp Pathol. 1988 Aug;99(2):187-203 [2846660.001]
  • [Cites] Toxicol Pathol. 1988;16(3):321-6 [3194653.001]
  • [Cites] Cell Tissue Res. 1988 Oct;254(1):225-31 [2461804.001]
  • [Cites] Oncogene Res. 1988;3(1):87-97 [3060799.001]
  • [Cites] Annu Rev Genet. 1988;22:479-519 [3071256.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Cell. 1989 Sep 8;58(5):803-5 [2673531.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6108-17 [2551499.001]
  • [Cites] Am J Pathol. 1989 Oct;135(4):679-95 [2552813.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1470-8 [2478587.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] Am J Surg Pathol. 1990 Feb;14(2):151-66 [1689123.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2417-26 [1693532.001]
  • [Cites] Semin Immunol. 1990 Jan;2(1):13-24 [1717051.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1161-7 [1957168.001]
  • [Cites] J Clin Invest. 1992 Jan;89(1):244-53 [1729274.001]
  • [Cites] Mol Biol Cell. 1992 Feb;3(2):211-20 [1550962.001]
  • [Cites] Development. 1992 Feb;114(2):521-32 [1592003.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Oncogene. 1992 Nov;7(11):2175-87 [1279498.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):99-105 [7677978.001]
  • [Cites] Cancer Treat Res. 1992;63:359-71 [1284027.001]
  • [Cites] Cell. 1993 Mar 26;72(6):835-46 [7681362.001]
  • [Cites] FASEB J. 1993 Jul;7(10):866-71 [8344486.001]
  • [Cites] Toxicol Pathol. 1993;21(2):206-18 [8210943.001]
  • [Cites] Immunol Today. 1993 Sep;14(9):445-59 [8216723.001]
  • [Cites] Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24 [8281615.001]
  • (PMID = 16309545.001).
  • [ISSN] 0959-9673
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / Antigens, Viral, Tumor; 0 / Biomarkers, Tumor; EC 2.7.1.40 / Pyruvate Kinase
  • [Other-IDs] NLM/ PMC2517450
  •  go-up   go-down


36. Gakiopoulou H, Korkolopoulou P, Levidou G, Thymara I, Saetta A, Piperi C, Givalos N, Vassilopoulos I, Ventouri K, Tsenga A, Bamias A, Dimopoulos MA, Agapitos E, Patsouris E: Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications. Br J Cancer; 2007 Oct 22;97(8):1124-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications.
  • Minichromosome maintenance proteins (MCM) have recently emerged as novel proliferation markers with prognostic implications in several tumour types.
  • This is the first study investigating MCM-2 and MCM-5 immunohistochemical expression in a series of ovarian adenocarcinomas and low malignant potential (LMP) tumours aiming to determine possible associations with clinicopathological parameters, the conventional proliferation index Ki-67, cell cycle regulators (p53, p27(Kip1), p21(WAF1) and pRb) and patients' outcome.
  • Immunohistochemistry was applied in a series of 43 cases of ovarian LMP tumours and 85 cases of adenocarcinomas.
  • The median MCM-2 and MCM-5 labelling indices (LIs) were significantly higher in adenocarcinomas compared to LMP tumours (P<0.0001 for both associations).
  • In adenocarcinomas, the levels of MCM-2 and MCM-5 increased significantly with advancing tumour stage (P=0.0052 and P=0.0180, respectively), whereas both MCM-2 and MCM-5 increased significantly with increasing tumour grade (P=0.0002 and P=0.0006, respectively) and the presence of bulky residual disease (P<0.0001 in both relationships).
  • [MeSH-major] Cell Cycle Proteins / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Nuclear Proteins / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Minichromosome Maintenance Complex Component 2. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Jun;31(6):698-704 [10872663.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):899-907 [16112007.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):64-70 [11163153.001]
  • [Cites] J Cell Sci. 2001 Apr;114(Pt 8):1447-54 [11282021.001]
  • [Cites] Int J Gynecol Cancer. 2001 May-Jun;11(3):187-93 [11437923.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2027-41 [11493639.001]
  • [Cites] Neuropathol Appl Neurobiol. 2001 Aug;27(4):305-13 [11532161.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2712-8 [11555583.001]
  • [Cites] Eur J Cancer. 2000 Dec;36(18):2317-28 [11094305.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):2984-97 [11595686.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4259-66 [11709570.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Pathobiology. 2001;69(3):150-8 [11872961.001]
  • [Cites] Br J Neurosurg. 2002 Feb;16(1):10-5 [11928726.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1075-81 [11948116.001]
  • [Cites] Gynecol Oncol. 2002 Jun;85(3):404-14 [12051866.001]
  • [Cites] Cancer J. 2002 May-Jun;8 Suppl 1:S22-30 [12075699.001]
  • [Cites] Int J Mol Med. 2002 Aug;10(2):161-8 [12119552.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):389-404 [12518363.001]
  • [Cites] Eur Urol. 2003 Feb;43(2):138-45 [12565771.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):185-97 [12620412.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):369-78 [12648589.001]
  • [Cites] Histol Histopathol. 2003 Jul;18(3):761-70 [12792888.001]
  • [Cites] J Oral Pathol Med. 2003 Sep;32(8):468-74 [12901728.001]
  • [Cites] J Surg Oncol. 2003 Sep;84(1):24-30 [12949987.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4306-13 [14645419.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1583-90 [15083189.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):2962-8 [15126326.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3103-11 [15126347.001]
  • [Cites] J Mol Biol. 2004 Jul 23;340(5):1197-206 [15236977.001]
  • [Cites] Pathobiology. 2004;71(4):193-200 [15263808.001]
  • [Cites] Control Clin Trials. 1981 Jun;2(2):93-113 [7273794.001]
  • [Cites] Eur J Biochem. 1986 Sep 15;159(3):529-34 [2428616.001]
  • [Cites] Biometrics. 1986 Sep;42(3):507-19 [3567285.001]
  • [Cites] J Cell Physiol. 2000 Mar;182(3):371-80 [10653604.001]
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6B):4935-45 [10697493.001]
  • [Cites] Exp Cell Res. 2005 Sep 10;309(1):56-67 [16005865.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):939-45 [16189522.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1295-300 [16278669.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Mar;132(3):163-70 [16328436.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2A):1071-5 [16619508.001]
  • [Cites] Lab Invest. 2001 Aug;81(8):1163-5 [11502867.001]
  • [Cites] Gene. 2000 Mar 7;245(1):13-20 [10713440.001]
  • [Cites] Arch Pathol Lab Med. 1987 Sep;111(9):794-5 [3632298.001]
  • [Cites] Nature. 1988 Apr 7;332(6164):546-8 [3357511.001]
  • [Cites] Biol Cell. 1991;72(1-2):47-50 [1756311.001]
  • [Cites] J Cell Sci. 1994 Jan;107 ( Pt 1):253-65 [8175912.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3312-9 [9214646.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3320-31 [9214647.001]
  • [Cites] Eur J Biochem. 1997 Jul 1;247(1):136-41 [9249019.001]
  • [Cites] Lab Invest. 1998 Jan;78(1):73-8 [9461123.001]
  • [Cites] Exp Cell Res. 1998 May 25;241(1):260-4 [9633535.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1256-65 [9697881.001]
  • [Cites] J Biol Chem. 1998 Sep 18;273(38):24543-9 [9733749.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1870-8 [10206307.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2121-32 [10473096.001]
  • [Cites] J Cell Sci. 2004 Nov 15;117(Pt 24):5875-86 [15522891.001]
  • [Cites] J Pathol. 2005 Jan;205(2):123-9 [15643673.001]
  • [Cites] Annu Rev Biochem. 1999;68:649-86 [10872463.001]
  • (PMID = 17940502.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / MCM5 protein, human; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  • [Other-IDs] NLM/ PMC2360432
  •  go-up   go-down


37. Simeonov R, Simeonova G: Computerized morphometry of mean nuclear diameter and nuclear roundness in canine mammary gland tumors on cytologic smears. Vet Clin Pathol; 2006 Mar;35(1):88-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computerized morphometry of mean nuclear diameter and nuclear roundness in canine mammary gland tumors on cytologic smears.
  • BACKGROUND: The use of computer-based image analysis systems in veterinary oncology has increased.
  • OBJECTIVES: The aim of this study was to define whether the morphometric parameters of mean nuclear diameter and nuclear roundness could be used to differentiate benign from malignant canine mammary gland tumors on cytologic specimens.
  • METHODS: Mean nuclear diameter and nuclear roundness were determined by computer-assisted morphometry of epithelial cells in Hemacolor-stained cytologic smears from normal canine mammary gland (n = 7) and from canine mammary adenomas (n = 8), tubulopapillary carcinomas (n = 9), and solid carcinomas (n = 6).
  • RESULTS: Significant differences (P <.001) were found in mean nuclear diameter and nuclear roundness among all tumor types and in comparison with normal canine mammary gland epithelial cells (except for nuclear roundness between tubulopapillary carcinomas and solid carcinomas).
  • CONCLUSIONS: The morphometric parameters of mean nuclear diameter and nuclear roundness can be used in the preoperative differentiation of benign from malignant canine mammary gland tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16511796.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Kedzia W, Goździcka-Józefiak A: [Mechanism of the cancerogenesis in cervix paraepidermal epithelium cells with chronic infection of oncogenic types of human papiloma virus]. Ginekol Pol; 2007 Sep;78(9):701-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mechanism of the cancerogenesis in cervix paraepidermal epithelium cells with chronic infection of oncogenic types of human papiloma virus].
  • The human papillomavirus family is composed of a large number of different and variably related types, each of which is associated with a characteristic set of epithelial lesions.
  • HPV 6 and 11 are frequently associated with benign condylomas, while HPV 16 and 18 are associated with malignant progression and cervical cancer.
  • The genome of papillomaviruses is composed of a circular double stranded DNA.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / genetics. Cervical Intraepithelial Neoplasia / pathology. Epithelial Cells / pathology. Papillomaviridae / genetics. Tumor Virus Infections / genetics. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / pathology


39. Nanni S, Priolo C, Grasselli A, D'Eletto M, Merola R, Moretti F, Gallucci M, De Carli P, Sentinelli S, Cianciulli AM, Mottolese M, Carlini P, Arcelli D, Helmer-Citterich M, Gaetano C, Loda M, Pontecorvi A, Bacchetti S, Sacchi A, Farsetti A: Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res; 2006 Feb;4(2):79-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer.
  • The histopathologic and molecular heterogeneity of prostate cancer and the limited availability of human tumor tissue make unraveling the mechanisms of prostate carcinogenesis a challenging task.
  • Our goal was to develop an ex vivo model that could be reliably used to define a prognostic signature based on gene expression profiling of cell cultures that maintained the tumor phenotype.
  • To this end, we derived epithelial cultures from tissue explanted from 59 patients undergoing radical prostatectomy or cistoprostatectomy because of prostate benign hyperplasia/prostate cancer or bladder carcinoma.
  • Cultures from normal/hyperplastic tissues with a prevalent luminal phenotype and from normal prostate epithelial tissue with basal phenotype (PrEC) served as controls.
  • From them, we derived an epithelial-restricted transcriptional signature that (a) differentiated normal from tumor cells and (b) clearly separated cancer-derived lines into two distinct groups, which correlated with indolent or aggressive clinical behavior of the disease.
  • Our findings provide (a) a method to expand human primary prostate carcinoma cells with a luminal phenotype, (b) a powerful experimental model to study primary prostate cancer biology, and (c) a novel means to characterize these tumors from a molecular genetic standpoint for prognostic and/or predictive purposes.
  • [MeSH-major] Biomarkers, Tumor / genetics. Epithelial Cells / metabolism. Gene Expression Profiling. Prostatic Neoplasms / genetics
  • [MeSH-minor] Aged. Cell Differentiation. Cells, Cultured. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Phenotype. Prognosis. Prostate / metabolism. Prostatectomy. Prostatic Hyperplasia / genetics. Prostatic Hyperplasia / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16513839.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


40. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, Pantel K: High incidence of EMMPRIN expression in human tumors. Int J Cancer; 2006 Oct 15;119(8):1800-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of EMMPRIN expression in human tumors.
  • Extracellular matrix metalloproteinase inducer expressed by tumor cells stimulates peritumoral fibroblasts to produce matrix metalloproteinases, thus contributing to tumor invasion and metastasis.
  • EMMPRIN expression was detected immunohistochemically using monoclonal antibodies MEM-M6/1 and HIM6 and tissue microarrays with 2,348 and 608 tissue samples from 129 distinct tumor types and 76 different normal tissues, respectively.
  • EMMPRIN expression was found in 112 of 129 tumor entities analyzed with malignant tumors being EMMPRIN positive more frequently than benign tumors.
  • A remarkable heterogeneity in EMMPRIN expression between tumor entities was observed.
  • There were a limited number of EMMPRIN-positive normal cell types including proliferatively active and differentiating epithelial cells, germ cells, myocardial cells in the left heart ventricle or vascular endothelial cells of the brain.
  • [MeSH-minor] Carbohydrate Metabolism. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Male. Protein Isoforms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16721788.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


41. Noske A, Denkert C, Schober H, Sers C, Zhumabayeva B, Weichert W, Dietel M, Wiechen K: Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer; 2005 Feb;41(3):461-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we analysed the expression of gelsolin in 241 matched cDNA pairs from human normal and tumour tissues using a Cancer Profiling Array.
  • On a protein level, we examined the expression of gelsolin in human ovarian cancer cell lines and in a set of 110 cases of human benign and malignant ovarian tumours.
  • Low levels of gelsolin protein were observed in four of six ovarian carcinoma cell lines, in contrast to its expression in normal ovarian surface epithelial cells.
  • In addition, we found a reduced expression of gelsolin in borderline tumours and ovarian carcinomas compared with the epithelium of normal ovaries and benign adenomas.
  • Re-expression of gelsolin in OAW42 and ES-2 cells resulted in a suppression of tumour cell survival in vitro.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Down-Regulation. Female. Humans. Immunohistochemistry. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691647.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gelsolin
  •  go-up   go-down


42. Popadiuk CM, Xiong J, Wells MG, Andrews PG, Dankwa K, Hirasawa K, Lake BB, Kao KR: Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. Clin Cancer Res; 2006 Apr 1;12(7 Pt 1):2216-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer.
  • In epithelial ovarian cancer, constitutively active Wnt signaling is restricted to one (endometrioid) tumor subtype.
  • The purpose of this study was to determine the level of expression and growth requirements of human Pygopus2 (hPygo2) protein in epithelial ovarian cancer.
  • EXPERIMENTAL DESIGN: Expression and subcellular localization of hPygo2 was determined in epithelial ovarian cancer cell lines and tumors using Northern blot, immunoblot, and immunofluorescence.
  • Immunohistochemistry was done on 125 archived patient epithelial ovarian cancer tumors representing all epithelial ovarian cancer subtypes.
  • T-cell factor-dependent transcription levels were determined in epithelial ovarian cancer cells using TOPflash/FOPflash in vivo assays.
  • RESULTS: All six epithelial ovarian cancer cell lines and 82% of the patient samples overexpressed nuclear hPygo2 compared with control cells and benign disease.
  • CONCLUSIONS: hPygo2 is unexpectedly widely expressed in, and required in the absence of, Wnt signaling for malignant growth of epithelial ovarian cancer, the deadliest gynecologic malignancy.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / drug effects. Neoplasms, Glandular and Epithelial / drug therapy. Oligodeoxyribonucleotides, Antisense / pharmacology. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Models, Animal. Drug Screening Assays, Antitumor. Female. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. In Vitro Techniques. Mice. Neoplasms, Experimental / therapy. Structure-Activity Relationship. Transplantation, Heterologous. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609037.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Oligodeoxyribonucleotides, Antisense; 0 / PYGO2 protein, human
  •  go-up   go-down


43. Kohrenhagen N, Volker HU, Kapp M, Dietl J, Kammerer U: Increased expression of galectin-1 during the progression of cervical neoplasia. Int J Gynecol Cancer; 2006 Nov-Dec;16(6):2018-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Galectin-1, a member of the beta-galactoside-binding family, is widely expressed in epithelial and immune cells.
  • Galectin-1 was found to be overexpressed in various cancer cells and the corresponding benign tissue.
  • Therefore, it has been described as a marker for tumor progression in some malignancies.
  • In the current study, the expression of galectin-1 was examined in 80 formalin-fixed, paraffin-embedded cervical tissues: 20 benign cervical specimen, 20 low-grade squamous intraepithelial lesions (LGSIL), 20 high-grade squamous intraepithelial lesions (HGSIL), and 20 invasive squamous cell carcinomas (ISCC).
  • Immunohistochemical analyses showed that the intensity of the galectin-1 expression on stromal cells next to the transformed cells increased according to the pathologic grade: benign cervical tissue < LGSIL < HGSIL < ISCC (P < 0.001).
  • The epithelial cells were always negative for galectin-1.


44. Drukier AK, Ossetrova N, Schors E, Krasik G, Grigoriev I, Koenig C, Sulkowski M, Holcman J, Brown LR, Tomaszewski JE, Schnall MD, Sainsbury R, Lokshin AE, Godovac-Zimmermann J: High-sensitivity blood-based detection of breast cancer by multi photon detection diagnostic proteomics. J Proteome Res; 2006 Aug;5(8):1906-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilot studies indicate that this methodology may also allow differentiation of malignant breast cancer from benign lesions and can provide similar sensitivity and specificity for other epithelial cancers such as prostate cancer, ovarian cancer and melanoma.
  • [MeSH-major] Biomarkers, Tumor / blood. Blood. Breast Neoplasms. Neoplasm Proteins / analysis. Photons. Proteomics / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunoassay / methods. Interleukin-6 / blood. Interleukin-8 / blood. Middle Aged. Prostate-Specific Antigen / blood. Sensitivity and Specificity. Statistics as Topic. Tumor Necrosis Factor-alpha / blood. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Blood.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889412.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Neoplasm Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


45. Oltmann SC, Garcia N, Barber R, Huang R, Hicks B, Fischer A: Can we preoperatively risk stratify ovarian masses for malignancy? J Pediatr Surg; 2010 Jan;45(1):130-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 424 patients were identified, with a mean age 12.5 years (range, 1 day to 19 years), without an age disparity between benign (12.54 years, 89%) and malignant (11.8 years, 11%) cases.
  • Imaging of benign neoplasms had a mean size of 8 cm (range, 0.9-36 cm) compared with malignancies at 17.3 cm (6.2-50 cm, P < .001).
  • Ultrasound or computed tomographic findings of a solid mass, although infrequent, were most commonly associated with malignancy (33%-60%), compared with reads of heterogeneous (15%-21%) or cystic (4%-5%) lesions.
  • The malignancies (n = 46) included germ cell (50%, n = 23), stromal (28%, n = 13), epithelial (17%, n = 8), and other (4%, n = 2).
  • Tumor markers obtained in 71% of malignancies were elevated in only 54%, whereas 6.5% of those sent in benign cases were similarly elevated.
  • CONCLUSION: This reported series of pediatric ovarian masses demonstrates that preoperative indicators that best predict an ovarian malignancy are a complaint of a mass or precocious puberty, a mass exceeding 8 cm or a mass with solid imaging characteristics.
  • Tumor markers, positive or negative, were not conclusive in all cases but useful for postoperative surveillance.
  • [MeSH-major] Ovarian Diseases / diagnosis. Ovarian Diseases / surgery. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Preoperative Care / methods
  • [MeSH-minor] Abdominal Pain / diagnosis. Age Factors. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Carcinoembryonic Antigen / blood. Child. Child, Preschool. Confidence Intervals. Diagnosis, Differential. Female. Humans. Infant. Neoplasm Staging. Neoplasms / blood. Neoplasms / diagnosis. Neoplasms / surgery. Ovary / pathology. Ovary / surgery. Prognosis. Puberty, Precocious / diagnosis. Risk Assessment

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20105592.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


46. Gunasekera RS, Sewgobind K, Desai S, Dunn L, Black HS, McKeehan WL, Patil B: Lycopene and lutein inhibit proliferation in rat prostate carcinoma cells. Nutr Cancer; 2007;58(2):171-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of grapefruit-derived and commercial lycopene and lutein preparations on androgen independent cultured malignant type II tumor cells [Dunning R3327AT3 or AT3 cells (androgen-responsive, slow-growing tumor cells with well developed epithelium and stroma)] were compared to their benign parent type I tumor epithelial cells (DTE).
  • No such effect was observed when benign DTE cells were examined, demonstrating selective inhibition of extremely malignant AT3 prostate cancer cells relative to their benign parent.
  • [MeSH-minor] Animals. Chromatography, High Pressure Liquid. Citrus paradisi. Dose-Response Relationship, Drug. Humans. Male. Rats. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640163.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 36-88-4 / Carotenoids; SB0N2N0WV6 / lycopene; X72A60C9MT / Lutein
  •  go-up   go-down


47. Nykopp TK, Rilla K, Sironen R, Tammi MI, Tammi RH, Hämäläinen K, Heikkinen AM, Komulainen M, Kosma VM, Anttila M: Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content. BMC Cancer; 2009;9:143
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hyaluronan, a tumor promoting extracellular matrix polysaccharide, is elevated in malignant epithelial ovarian tumors, and associates with an unfavorable prognosis.
  • METHODS: Normal ovaries (n = 5) and 34 serous epithelial ovarian tumors, divided into 4 groups: malignant grades 1+2 (n = 10); malignant grade 3 (n = 10); borderline (n = 4) and benign epithelial tumors (n = 10), were analyzed for mRNA by real-time RT-PCR and compared to hyaluronidase activity, hyaluronan staining, and HAS1-3 immunoreactivity in tissue sections of the same specimens.
  • CONCLUSION: The results indicate that in serous epithelial ovarian malignancies HAS expression is not consistently elevated but HYAL1 expression is significantly reduced and correlates with the accumulation of hyaluronan. (233 words).

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2009 Mar;174(3):1027-36 [19218337.001]
  • [Cites] Matrix Biol. 2008 Oct;27(8):653-60 [18762256.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3361-70 [11058590.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):35111-22 [11451952.001]
  • [Cites] Matrix Biol. 2001 Dec;20(8):499-508 [11731267.001]
  • [Cites] Matrix Biol. 2001 Dec;20(8):509-14 [11731268.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4593-6 [11717318.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38013-20 [12145277.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):212-9 [12397638.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6410-3 [12438225.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):359-64 [14506734.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5318-24 [14614016.001]
  • [Cites] Int J Cancer. 2004 Mar 20;109(2):247-52 [14750176.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7832-7 [8755562.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1228-32 [9102203.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):13997-4000 [9206724.001]
  • [Cites] Int J Cancer. 1997 Nov 4;73(3):327-31 [9359477.001]
  • [Cites] Lab Invest. 1998 Aug;78(8):987-1003 [9714186.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):207-12 [15386412.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):65-72 [15358636.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):154-9 [15543203.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2243-50 [15781637.001]
  • [Cites] Int J Oncol. 2005 Jun;26(6):1681-9 [15870886.001]
  • [Cites] Pathol Biol (Paris). 2005 Sep;53(7):372-82 [16085113.001]
  • [Cites] Arkh Patol. 2005;Suppl:1-64 [16108150.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7782-9 [16140946.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):483-91 [18199543.001]
  • [Cites] Glycobiology. 2008 Apr;18(4):280-9 [18234732.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):150-5 [10646867.001]
  • (PMID = 19435493.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9004-61-9 / Hyaluronic Acid; EC 2.4.1.17 / Glucuronosyltransferase; EC 2.4.1.212 / hyaluronan synthase; EC 3.2.1.35 / Hyaluronoglucosaminidase
  • [Other-IDs] NLM/ PMC2689240
  •  go-up   go-down


48. Adolf K, Wagner L, Bergh A, Stattin P, Ottosen P, Borre M, Birkenkamp-Demtröder K, Orntoft TF, Tørring N: Secretagogin is a new neuroendocrine marker in the human prostate. Prostate; 2007 Apr 1;67(5):472-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Neuroendocrine (NE) differentiation in prostate cancer (PCa), promoted by NE cell secreted products, appears to be associated with tumor progression, poor prognosis, and hormone-refractory disease.
  • We recently reported secretagogin, a hexa-EF-hand Ca(2+) binding protein, as a novel NE marker in carcinoid tumors of the lung and the gastrointestinal tract.
  • METHODS: We analyzed immunoreactivity for secretagogin, chromogranin A (CgA), neuron specific enolase (NSE), and synaptophysin (SYN) in consecutive sections from 87 formalin-fixed paraffin-embedded (FFPE) benign hyperplastic (n = 10) and prostate adenocarcinoma (n = 77) specimens.
  • RESULTS: Secretagogin is cytoplasmic and nuclear expressed in NE and NE differentiated cells, and to a lesser extent in epithelial cells, in the benign prostate and prostate adenocarcinoma cells.
  • Secretagogin stained 82% (46/56) of benign and 71% (48/68) of prostate adenocarcinomas and co-localized with the NE markers CgA and NSE.
  • The expression of secretagogin is significantly correlated to CgA (P < 0.001) and NSE (P < 0.048) in prostate adenocarcinoma and to CgA in normal epithelium (P < 0.028).
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Calcium-Binding Proteins / biosynthesis. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285592.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Chromogranin A; 0 / SCGN protein, human; 0 / Secretagogins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


49. Plaza JA, Wakely PE Jr, Suster S: Lipoblastic nerve sheath tumors: report of a distinctive variant of neural soft tissue neoplasm with adipocytic differentiation. Am J Surg Pathol; 2006 Mar;30(3):337-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipoblastic nerve sheath tumors: report of a distinctive variant of neural soft tissue neoplasm with adipocytic differentiation.
  • Benign nerve sheath tumors of soft tissue can occasionally adopt unusual or unfamiliar morphologic appearances that may introduce difficulties for diagnosis, such as multinucleation, bizarre nuclei, intranuclear vacuoles, and other degenerative changes.
  • Tumor cells adopting a signet-ring or lipoblast-like configuration, however, are mostly associated with epithelial malignancies, liposarcoma and melanoma, and have been only rarely observed in spindle cell tumors of soft tissue.
  • We report 5 cases of benign nerve sheath neoplasms that displayed prominent signet-ring cells with lipoblast-like features.
  • Four tumors predominantly showed features of schwannoma and one of neurofibroma; however, intimately admixed with the spindle cell population, there were also numerous scattered mature adipocytes as well as lipoblast-like cells displaying a signet-ring cell appearance.
  • The presence of mature fat and signet-ring lipoblast-like cells within a nerve sheath neoplasm is quite rare and may signify a process of aberrant differentiation.
  • Neurogenic tumors should be added in the differential diagnosis of spindle cell tumors capable of displaying prominent signet-ring cell features.

  • Genetic Alliance. consumer health - Nerve sheath neoplasm.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538053.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Ilie M, Hofman V, Pedeutour F, Attias R, Santini J, Hofman P: Oncocytic lipoadenoma of the parotid gland: Immunohistochemical and cytogenetic analysis. Pathol Res Pract; 2010 Jan 15;206(1):66-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Salivary gland oncocytic lipoadenoma is an exceptional benign tumor composed of mature adipose tissue associated with a mixture of oncocytes.
  • A 64-year-old male developed a left parotid gland, well-encapsulated tumor measuring 3.5 x 3 cm(2), showing mature fat cells associated with oncocytic changes of epithelial components.
  • Immunohistochemistry showed a dual epithelial population with ductal (positivity for AE1/AE3, CK19, CK7 antibodies) and basal-cell (positivity for p63, CK14, CK5,6 antibodies) differentiation in oncocytic areas.
  • [MeSH-minor] Disease-Free Survival. Humans. Immunohistochemistry. Lipoma / metabolism. Lipoma / pathology. Lipoma / surgery. Male. Middle Aged. Neoplasm Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19346081.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


51. Chen G, Zhang FR, Ren J, Tao LH, Shen ZY, Lv Z, Yu SJ, Dong BF, Xu LY, Li EM: Expression of fascin in thyroid neoplasms: a novel diagnostic marker. J Cancer Res Clin Oncol; 2008 Sep;134(9):947-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Fascin, an actin-bundling protein, is markedly upregulated in several epithelial tumors and its expression often correlates with high-grade, extensive invasion, and distant metastasis.
  • However, reports about fascin expression in endocrine tumors remain rare.
  • CONCLUSION: Fascin may be a novel marker to distinguish thyroid carcinoma from benign lesions and may be involved in the proliferation and metastasis of papillary carcinoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carrier Proteins / metabolism. Microfilament Proteins / metabolism. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2006 Sep;59(9):958-64 [16524962.001]
  • [Cites] Cell Motil Cytoskeleton. 2001 Feb;48(2):109-20 [11169763.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] J Cutan Pathol. 2002 Aug;29(7):430-8 [12139639.001]
  • [Cites] Oncogene. 2000 Oct 5;19(42):4864-75 [11039904.001]
  • [Cites] In Vivo. 1996 Mar-Apr;10(2):153-60 [8744794.001]
  • [Cites] J Virol. 1994 Nov;68(11):7320-8 [7933116.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):543-62 [9033270.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1271-81 [8794867.001]
  • [Cites] J Immunol. 2001 Jan 1;166(1):338-45 [11123310.001]
  • [Cites] Cancer. 1983 Nov 15;52(10):1849-55 [6313176.001]
  • [Cites] Trends Cardiovasc Med. 2004 Aug;14(6):221-6 [15451513.001]
  • [Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]
  • [Cites] Surgery. 1988 Dec;104(6):947-53 [3194846.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):741-6 [16084942.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] J Immunol. 1998 Apr 15;160(8):3776-82 [9558080.001]
  • (PMID = 18343949.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Ki-67 Antigen; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


52. Knight JF, Shepherd CJ, Rizzo S, Brewer D, Jhavar S, Dodson AR, Cooper CS, Eeles R, Falconer A, Kovacs G, Garrett MD, Norman AR, Shipley J, Hudson DL: TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. Br J Cancer; 2008 Dec 02;99(11):1849-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The disease may involve the inappropriate expression of genes that normally control the proliferation of epithelial cells in the basal layer and their differentiation into luminal cells.
  • RNA from basal and luminal cells isolated from benign tissue by immunoguided laser-capture microdissection was subjected to expression profiling.
  • [MeSH-major] Biomarkers, Tumor / analysis. DNA-Binding Proteins / biosynthesis. Nuclear Proteins / biosynthesis. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Proto-Oncogene Proteins c-cbl / biosynthesis. Transcription Factors / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Epithelial Cells / metabolism. Epithelial Cells / pathology. Fluorescent Antibody Technique. Gene Expression. Gene Expression Profiling. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Microdissection. Middle Aged. Polymerase Chain Reaction. Prognosis. RNA, Small Interfering. Tissue Array Analysis. Transfection

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biol Cell. 2000 Oct;11(10):3397-410 [11029044.001]
  • [Cites] Clin Exp Metastasis. 2004;21(7):571-9 [15787094.001]
  • [Cites] Prostate. 2001 Feb 1;46(2):142-53 [11170142.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10413-22 [11136726.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Apr;2(4):294-307 [11283727.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2167-78 [11493652.001]
  • [Cites] Mol Cell. 2001 Nov;8(5):995-1004 [11741535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11355-60 [16051706.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] J Cell Physiol. 2006 Oct;209(1):21-43 [16741904.001]
  • [Cites] Oncogene. 2006 Oct 19;25(49):6528-37 [16751809.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):528-36 [17234760.001]
  • [Cites] Differentiation. 2007 Jan;75(1):35-48 [17244020.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):159-66 [17361204.001]
  • [Cites] Oncogene. 2007 Mar 15;26(12):1757-68 [16964284.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5221-30 [17545602.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6796-805 [17638891.001]
  • [Cites] Mol Biol Cell. 2007 Jul;18(7):2481-90 [17475774.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6238-43 [17369840.001]
  • [Cites] Expert Rev Mol Diagn. 2007 Sep;7(5):647-57 [17892370.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2747-61 [17974916.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6579-84 [18006757.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):253-63 [17637754.001]
  • [Cites] Dev Cell. 2008 Mar;14(3):377-87 [18258485.001]
  • [Cites] Dev Cell. 2008 Mar;14(3):388-98 [18258486.001]
  • [Cites] Dev Cell. 2008 Mar;14(3):315-6 [18331708.001]
  • [Cites] Mol Cell Biol. 2008 May;28(10):3177-89 [18332127.001]
  • [Cites] Prostate. 2008 Jun 15;68(9):1007-24 [18398820.001]
  • [Cites] BMC Genomics. 2008;9:246 [18501003.001]
  • [Cites] Prostate. 2008 Aug 1;68(11):1215-22 [18500693.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5146-52 [16033829.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48889-98 [12376544.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19286-91 [12637527.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):464-9 [14695896.001]
  • [Cites] Eur Urol. 2004 Aug;46(2):271-2 [15245824.001]
  • [Cites] J Histochem Cytochem. 2004 Aug;52(8):1083-90 [15258184.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):5871-9 [15184867.001]
  • [Cites] Adv Cancer Res. 2004;91:31-67 [15327888.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6940-4 [1458483.001]
  • [Cites] J Urol. 1993 Jan;149(1):170-3 [7678041.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Oncogene. 1994 Oct;9(10):2785-91 [8084583.001]
  • [Cites] J Cell Biol. 1995 Mar;128(6):1019-28 [7896868.001]
  • [Cites] J Urol. 1995 Jul;154(1):293-8 [7539865.001]
  • [Cites] Arch Dermatol Res. 1995;287(8):740-6 [8554386.001]
  • [Cites] Prostate. 1996 Feb;28(2):98-106 [8604398.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):3924-36 [9199327.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1225-31 [9214606.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):61-6 [9916919.001]
  • [Cites] J Pathol. 1999 Apr;187(5):563-6 [10398122.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):391-9 [10453283.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1462-8 [15619204.001]
  • [Cites] J Histochem Cytochem. 2001 Feb;49(2):271-8 [11156695.001]
  • (PMID = 19002168.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501019; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RNA, Small Interfering; 0 / TEAD1 protein, human; 0 / Transcription Factors; EC 2.3.2.27 / Proto-Oncogene Proteins c-cbl; EC 6.3.2.- / CBL protein, human
  • [Other-IDs] NLM/ PMC2600693
  •  go-up   go-down


53. Tallon B, Cerroni L: Where pigmented pilomatricoma and melanocytic matricoma collide. Am J Dermatopathol; 2010 Dec;32(8):769-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilomatricoma and matricoma are 2 benign epithelial tumours derived from the hair matrix.
  • Although containing the same constituent cells, the silhouette differs, with matricoma comprised of a predominantly solid basaloid proliferation with only focal areas of shadow cell formation.
  • The recently described melanocytic matricoma appears to be a similar tumor with numerous interspersed melanocytes.
  • Comparison of these tumors with a further case of melanocytic matricoma led to a critical analysis of the relationship of pilomatricoma, matricoma, and melanocytic matricoma.
  • [MeSH-major] Hair Diseases / pathology. Melanocytes / pathology. Pilomatrixoma / pathology. Skin Neoplasms / pathology. Skin Pigmentation
  • [MeSH-minor] Adolescent. Aged. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Cell Proliferation. Child. Diagnosis, Differential. Female. Humans. Hyperplasia. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / analysis. Predictive Value of Tests. Retrospective Studies. S100 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881831.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Melan-A 51-73 peptide; 0 / Neoplasm Proteins; 0 / S100 Proteins
  •  go-up   go-down


54. Misra S, Toole BP, Ghatak S: Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem; 2006 Nov 17;281(46):34936-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells.
  • Hyaluronan (HA) is enriched in the pericellular matrices of many malignant human tumors, and manipulations of HA interactions have strong effects on tumor progression in animal models.
  • On the other hand, inhibition of constitutive HA-tumor cell interactions in malignant cells inhibits these properties.
  • On the other hand, we show that these RTKs are activated in phenotypically normal or relatively benign tumor cells by experimentally increasing HA production.
  • [MeSH-major] Carcinoma / metabolism. Epithelial Cells / metabolism. Hyaluronic Acid / metabolism. Receptor Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Breast Neoplasms / metabolism. Cell Line, Tumor. Colonic Neoplasms / metabolism. Female. Humans. Male. Prostatic Neoplasms / metabolism. Signal Transduction


55. Huang J, Wu C, di Sant'Agnese PA, Yao JL, Cheng L, Na Y: Function and molecular mechanisms of neuroendocrine cells in prostate cancer. Anal Quant Cytol Histol; 2007 Jun;29(3):128-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign prostate contains luminal epithelial cells, basal cells and a minor component of neuroendocrine cells whose function may be to regulate the growth, differentiation and secretory function of the prostate gland.
  • Neuroendocrine (NE) cells are also present in prostate cancer (PC), and many studies have shown that their number increases in high-grade and high-stage tumors, particularly in hormonally treated and hormone-refractory (androgen independent) PC.
  • Instead, these cells may be enriched after the therapy and they may establish paracrine networks to stimulate androgen-independent proliferation of PC, leading to tumor recurrence.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672372.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


56. Sakai T, Fujimori M, Tominaga Y, Kanai T, Ito K, Shingu K, Amano J, Kushima H, Tsuchiya S: A case of unilateral gravid macromastia in 23-year-old Japanese woman associated with elevated serum CA19-9. Breast Cancer; 2005;12(3):238-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The epithelial cells were positive for CA19-9 on immunohistochemical staining.
  • This benign tumor is sometimes difficult to distinguish from malignant tumors since it shows few histological characteristics and grows rapidly.
  • Attention is necessary to diagnose tumors of the breast during pregnancy.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110297.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


57. Zhang S, Wei L, Zhang A, Zhang L, Yu H: RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines. OMICS; 2009 Aug;13(4):307-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines.
  • RUNX3 is an important tumor suppressor gene located on human chromosome 1p36.1, and many tumors do not express it due to methylation of the promoter region of the CpG island.
  • The molecular mechanisms involved in RUNX3 gene expression and epithelial ovarian cancer are not fully understood.
  • The methylation of the RUNX3 gene promoter region was measured in 32 primary epithelial ovarian cancer samples and corresponding nonmalignant ovarian tissues, 36 benign epithelial ovarian tumor tissues, and 10 normal ovarian tissues by methylation-specific PCR (MSP) and RT-PCR.
  • We detected RUNX3 methylation in 53.1% of primary ovarian cancer tumors, 16.7% of benign ovarian tumors, and 28% of nonmalignant tissues surrounding ovarian cancers.
  • [MeSH-minor] Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Cell Line, Tumor. CpG Islands. DNA Modification Methylases / antagonists & inhibitors. Enzyme Inhibitors / pharmacology. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Promoter Regions, Genetic. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645591.001).
  • [ISSN] 1557-8100
  • [Journal-full-title] Omics : a journal of integrative biology
  • [ISO-abbreviation] OMICS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 3 Subunit; 0 / Enzyme Inhibitors; 0 / RNA, Messenger; 0 / Runx3 protein, human; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; M801H13NRU / Azacitidine
  •  go-up   go-down


58. Ravindranath MH, Muthugounder S, Presser N, Ye X, Brosman S, Morton DL: Endogenous immune response to gangliosides in patients with confined prostate cancer. Int J Cancer; 2005 Sep 1;116(3):368-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immune and resorcinol staining detected the presence of gangliosides GM3, GM2, GD3, GD2 and GD1a but not GM1a, GD1b or GT1b in the extracts of normal prostatic epithelial cells (PrEC) and neoplastic androgen-insensitive (PC-3, DU145) and -sensitive (LNCaP-FGC and LNCaP-FGC-10) CaP cells.
  • Using a sensitive ELISA, developed and validated in our laboratory, the titers of IgM against 8 gangliosides from sera of patients with benign prostatic hyperplasia (BPH) (n = 11), organ-confined (T1/T2, n = 36) and unconfined (T3/T4, n = 27) CaP and age-matched healthy men (n = 11) were determined double-blinded.
  • This finding together with identification of GD1a as a major ganglioside in CaP cell lines and with the accruing studies on the immunosuppressive nature of GD1a indicates that augmentation of anti-GD1a IgM in confined CaP may signify an early endogenous immune response to eliminate a "danger signal" from tumor microenvironment and circulation.
  • [MeSH-minor] Aged. Aged, 80 and over. Antibody Formation. Case-Control Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prostatic Hyperplasia / immunology. Prostatic Hyperplasia / pathology. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] NIH Guide Grants Contracts. 2012 Aug 10;:NOT-OD-12-131 [22905365.001]
  • [ErratumIn] Int J Cancer. 2015 Feb 15;136(4):E204-6
  • (PMID = 15818621.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA107831-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gangliosides; 0 / Immunoglobulin M
  •  go-up   go-down


59. Orzechowska-Wylegała B, Jedrzejewski P, Wylegała E, Steplewska K: Recurrent benign pleomorphic adenoma of the lacrimal gland--a case report. Klin Oczna; 2008;110(7-9):301-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent benign pleomorphic adenoma of the lacrimal gland--a case report.
  • Benign pleomorphic adenoma (mixed tumor) is the most frequently occurring tumor of epithelial origin.
  • This study is a description of the therapeutic management of a patient with recurrent pleomorphic adenoma of the lacrimal gland.
  • In 1996, a 35 year old male patient underwent surgery to remove a tumor of the left orbit.
  • In 2005, from a cut along the upper-outer edge of the left orbit, an elastic and soft tumor 1 cm in diameter was removed from soft tissues of the upper eyelid.
  • An eyelid nodule of 0.8 mm in diameter was removed together with an elastic and hard tumor of size 2.5 x 1 cm.
  • The result of the histopathological examination of the palpebral tumor was pseudocystic tumor and of the orbital tumor was pleomorphic adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112866.001).
  • [ISSN] 0023-2157
  • [Journal-full-title] Klinika oczna
  • [ISO-abbreviation] Klin Oczna
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


60. Vigneswaran N, Beckers S, Waigel S, Mensah J, Wu J, Mo J, Fleisher KE, Bouquot J, Sacks PG, Zacharias W: Increased EMMPRIN (CD 147) expression during oral carcinogenesis. Exp Mol Pathol; 2006 Apr;80(2):147-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gene expression profiling of oral premalignant (OPM) cells and normal oral epithelial (NOR) cells showed that EMMPRIN expression was markedly upregulated in OPM cells compared to NOR cells.
  • EMMPRIN expression was limited to basal cells of normal, benign hyperkeratotic and inflammatory (lichen planus) oral mucosa.
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell. Cell Line, Tumor. Epithelial Cells / cytology. Female. Gene Expression Profiling. Humans. Keratinocytes / cytology. Leukoplakia, Oral / pathology. Microarray Analysis. Middle Aged. Mouth Mucosa / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310185.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / DE13150; United States / NIDCR NIH HHS / DE / DE14395
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


61. Wu G, Hou W, Zhao Y, Wang E, Fang C, Liu S, Song J: [Clinical value of capture of cancer cells in pleural fluid of patients with lung cancer by cytochip]. Zhongguo Fei Ai Za Zhi; 2005 Jun 20;8(3):195-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Immunocytochemistry is valuabale in differentiating malignant fluids from benign ones.
  • However, the diagnostic value of a single tumor marker is limited.
  • METHODS: A new pattern cytochip was developed to immunize hybridization of cells in pleural fluids of patients with 42 lung cancers and with 20 lung benign lesions.
  • Ten antibodies were fixed on the cytochip, they were epithelial specific antigen (ESA), CD44V6, ND-1, T cell (CD3), CD45RO, B cell (CD20), CD79a, Hodgkin's cell (CD15), CD30 and macrophage (CD68).
  • The positive numbers of ESA, CD44V6, ND-1 were 35, 30, 38 respectively in pleural fluids of 42 patients with luog cancers; lymphocytes and neutrophils were found on the 1 ESA and 1 ND-1 respectively, and only lymphocytes were found on the 3 CD44V6 in 20 ones with lung benign lesions; the other 7 antibodies did not capture cancer cells except for lymphocytes, neutrophils and macrophages from two pleural fluids.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21190618.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


62. Lemaire R, Menguellet SA, Stauber J, Marchaudon V, Lucot JP, Collinet P, Farine MO, Vinatier D, Day R, Ducoroy P, Salzet M, Fournier I: Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J Proteome Res; 2007 Nov;6(11):4127-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-five ovary carcinomas (stages III and IV) and 23 benign ovaries were directly analyzed using MALDI-TOF MS.
  • The validation, using immunocytochemistry, confirmed the epithelial localization of this fragment with nucleus localization in benign epithelial cells and a cytoplasmic localization in carcinoma cells.
  • This indicates that this antibody could be used to discriminate the borderline tumor cases.
  • [MeSH-major] Biomarkers / chemistry. Biomarkers, Tumor / chemistry. Gene Expression Regulation, Neoplastic. Muscle Proteins / chemistry. Ovarian Neoplasms / metabolism. Proteasome Endopeptidase Complex / chemistry. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Antigens, Neoplasm / chemistry. Biopsy. Carcinoma / metabolism. Female. Humans. Immunohistochemistry / instrumentation. Immunohistochemistry / methods. Spectrometry, Mass, Electrospray Ionization

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17939699.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Muscle Proteins; 0 / PSME1 protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


63. Hsiao YH, Lien HC, Hwa HL, Kuo WH, Chang KJ, Hsieh FJ: SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J; 2010 May-Jun;16(3):305-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma.
  • The purpose of this study was to characterize the immunohistochemical distribution of secreted protein acidic and rich in cystein (SPARC) in benign and malignant breast tumors of different histologic types and define its association with the outcome of invasive ductal carcinoma (IDC) patients.
  • A total of 286 samples of benign and malignant breast lesions between 1994 and 2005 were retrieved from National Taiwan University Hospital.
  • Secreted protein acidic and rich in cystein was not expressed in benign breast phylloides and all benign breast tumors, while expressed in 17.2% of IDC, 85% of metaplastic carcinoma of the breast (MCB), and all malignant breast phylloides.
  • Secreted protein acidic and rich in cystein was strongly expressed in mesenchymal components of MCB and expression levels in epithelial components were variable.
  • Individuals with positive SPARC expression had 2.34 times higher hazard of death compared with those with negative SPARC expression after adjusting for factors including positive lymph node, TNM tumor stage, estrogen receptor, and progesterone receptor.
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging. Proportional Hazards Models

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210803.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Osteonectin
  •  go-up   go-down


64. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM: Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia; 2008 Feb;10(2):177-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TMPRSS2-ERG gene fusions are the predominant molecular subtype of prostate cancer.
  • Introduction of the ERG gene fusion product into primary or immortalized benign prostate epithelial cells induced an invasion-associated transcriptional program but did not increase cellular proliferation or anchorage-independent growth.
  • Importantly, VCaP cells and benign prostate cells overexpressing ERG directly engage components of the plasminogen activation pathway to mediate cellular invasion, potentially representing a downstream ETS target susceptible to therapeutic intervention.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9437-42 [10931945.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):73-80 [18172298.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):222-4 [11175795.001]
  • [Cites] In Vivo. 2001 Mar-Apr;15(2):163-8 [11317522.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(5):1495-503 [11839815.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2884-9 [11854455.001]
  • [Cites] Lancet. 2003 Mar 15;361(9361):955-64 [12648986.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3877-82 [12873976.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):6005-12 [12955079.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):223-38 [14522256.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]
  • [Cites] J Clin Invest. 2004 Mar;113(6):913-23 [15067324.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10602-7 [15249664.001]
  • [Cites] Curr Med Chem. 2004 Sep;11(17):2323-34 [15379715.001]
  • [Cites] FEBS Lett. 1987 Apr 6;214(1):187-91 [3106085.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13887-92 [9811896.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4180-4 [10485450.001]
  • [Cites] Genome Biol. 2005;6(3):R22 [15774023.001]
  • [Cites] Front Biosci. 2006;11:479-91 [16146745.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3396-400 [16585160.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):717-9 [16575875.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5012-20 [16707422.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):465-9 [16820092.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):79-87 [16546322.001]
  • [Cites] BMC Genomics. 2006;7:92 [16638148.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8337-41 [16951139.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8347-51 [16951141.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1760-71 [16931909.001]
  • [Cites] Neoplasia. 2006 Oct;8(10):826-32 [17032499.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10242-6 [17079440.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10658-63 [17108102.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Mod Pathol. 2007 Apr;20(4):467-73 [17334351.001]
  • [Cites] Oncol Rep. 2007 May;17(5):1033-6 [17390040.001]
  • [Cites] Neoplasia. 2007 Mar;9(3):200-6 [17401460.001]
  • [Cites] Mod Pathol. 2007 May;20(5):538-44 [17334343.001]
  • [Cites] Oncogene. 2007 Apr 19;26(18):2667-73 [17043636.001]
  • [Cites] PLoS Med. 2007 Apr;4(4):e122 [17425403.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] Neoplasia. 2007 May;9(5):443-54 [17534450.001]
  • [Cites] Cancer Biol Ther. 2007 Jan;6(1):40-5 [17172822.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4596-9 [17237811.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):595-9 [17671502.001]
  • [Cites] J Clin Pathol. 2007 Nov;60(11):1238-43 [17259299.001]
  • [Cites] Annu Rev Pathol. 2006;1:243-71 [18039115.001]
  • [Cites] Endocrinology. 2000 Dec;141(12):4698-710 [11108285.001]
  • (PMID = 18283340.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / R01 CA102872; United States / NCI NIH HHS / CA / U01 CA111275; United States / NCI NIH HHS / CA / UO1 CA111275-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / ERG protein, human; 0 / Oncogene Proteins, Fusion; 0 / TMPRSS2-ERG fusion protein, human; 0 / Trans-Activators; EC 3.4.21.- / Plasminogen Activators
  • [Other-IDs] NLM/ PMC2244693
  •  go-up   go-down


65. Marocchio LS, Pereira MC, Soares CT, Oliveira DT: Oral plexiform neurofibroma not associated with neurofibromatosis type I: case report. J Oral Sci; 2006 Sep;48(3):157-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was histopathologically analyzed and an immunohistochemical panel comprising S-100 protein, epithelial membrane antigen (EMA), collagen IV, and CD34 was performed.
  • Subjacent to the oral epithelium, tactile-like bodies were also detected.
  • On the basis of this report, we would like to emphasize that plexiform neurofibroma can occur in the oral cavity as a benign isolated tumor in patients without other stigmata of NF-1.


66. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, Wang X: Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res; 2005 Jun 15;65(12):5153-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using malignant and nonmalignant prostate tissues, we found that TWIST expression was highly expressed in the majority (90%) of prostate cancer tissues but only in a small percentage (6.7%) of benign prostate hyperplasia.
  • More importantly, inactivation of TWIST suppressed migration and invasion abilities of androgen-independent prostate cancer cells, which was correlated with induction of E-cadherin expression as well as morphologic and molecular changes associated with mesenchymal to epithelial transition.
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / physiology. Cell Line, Tumor. Epithelial Cells / pathology. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Male. Mesoderm / pathology. Neoplasm Invasiveness. Paclitaxel / pharmacology. Transfection. Twist Transcription Factor. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958559.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Transcription Factors; 0 / Twist Transcription Factor; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


67. Sisci D, Morelli C, Garofalo C, Romeo F, Morabito L, Casaburi F, Middea E, Cascio S, Brunelli E, Andò S, Surmacz E: Expression of nuclear insulin receptor substrate 1 in breast cancer. J Clin Pathol; 2007 Jun;60(6):633-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To assess whether nuclear IRS-1 is present in breast cancer and non-cancer mammary epithelium, and whether it correlates with other markers, especially ERalpha.
  • RESULTS: Median nuclear IRS-1 expression was found to be low in normal mammary epithelial cells (1.6%) and high in benign tumours (20.5%), ductal grade 2 carcinoma (11.0%) and lobular carcinoma (approximately 30%).
  • Median ERalpha expression in normal epithelium, benign tumours, ductal cancer grade 2 and 3, and lobular cancer grade 2 and 3 were 10.5, 20.5, 65.0, 0.0, 80 and 15%, respectively.
  • Nuclear IRS-1 and ERalpha positively correlated in ductal cancer (p<0.001) and benign tumours (p<0.01), but were not associated in lobular cancer and normal mammary epithelium.
  • In ductal carcinoma, both nuclear IRS-1 and ERalpha negatively correlated with tumour grade, size, mitotic index and lymph node involvement.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Cell Nucleus / metabolism. Phosphoproteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Cytoplasm / metabolism. Estrogen Receptor alpha / metabolism. Female. Humans. Immunoenzyme Techniques. Insulin Receptor Substrate Proteins. Mammary Glands, Human / metabolism. Microscopy, Confocal. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9817-24 [11139588.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):35-46 [15965906.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6747-54 [11559546.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):197-209 [11566611.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 2;288(3):685-9 [11676497.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):17231-8 [11877394.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):32078-85 [12063262.001]
  • [Cites] J Cell Physiol. 2003 Feb;194(2):108-16 [12494449.001]
  • [Cites] Oncogene. 2003 Jun 26;22(26):4007-16 [12821935.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6589-97 [14528284.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):873-7 [14601044.001]
  • [Cites] Metabolism. 2003 Dec;52(12):1606-11 [14669164.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):794-801 [14710360.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9272-6 [15197263.001]
  • [Cites] Oncogene. 2004 Sep 30;23(45):7517-26 [15318176.001]
  • [Cites] J Clin Invest. 1973 Jan;52(1):73-7 [4345203.001]
  • [Cites] Monogr Pathol. 1984;(25):149-74 [6377047.001]
  • [Cites] Bull Cancer. 1989;76(3):311-9 [2544239.001]
  • [Cites] Clin Chem. 1993 Jun;39(6):1345-6 [7684958.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3736-40 [8339284.001]
  • [Cites] Eur J Cancer. 1994;30A(3):307-11 [8204350.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):381-400 [8004612.001]
  • [Cites] Trends Biochem Sci. 1994 Jul;19(7):289-93 [8048169.001]
  • [Cites] J Cell Biochem. 2000 Jan;76(4):605-14 [10653980.001]
  • [Cites] J Biol Chem. 2000 Apr 28;275(17):12565-71 [10777546.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):95-105 [10791772.001]
  • [Cites] Prev Vet Med. 2000 May 30;45(1-2):23-41 [10802332.001]
  • [Cites] Heart. 2000 Jul;84(1):71-8 [10862595.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):506-13 [11102895.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5574-81 [11114737.001]
  • [Cites] Breast Cancer Res Treat. 1994;32(1):85-95 [7529598.001]
  • [Cites] Science. 1995 Dec 1;270(5241):1491-4 [7491495.001]
  • [Cites] Endocrinology. 1996 May;137(5):1735-44 [8612509.001]
  • [Cites] EMBO J. 1996 Mar 15;15(6):1292-300 [8635462.001]
  • [Cites] Ann N Y Acad Sci. 1996 Apr 30;784:189-201 [8651569.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:615-58 [8725404.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2606-10 [9205064.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3079-83 [9242428.001]
  • [Cites] Diabetologia. 1997 Jul;40 Suppl 2:S2-17 [9248696.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):828-34 [9311601.001]
  • [Cites] J Pathol. 1997 Dec;183(4):412-7 [9496257.001]
  • [Cites] Breast Cancer Res Treat. 1998 Feb;47(3):295-302 [9516083.001]
  • [Cites] Recent Prog Horm Res. 1998;53:119-38 [9769706.001]
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1429-36 [9815941.001]
  • [Cites] Clin Cancer Res. 1996 Dec;2(12):2037-42 [9816164.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):103-9 [9815544.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Dec 18;253(2):315-9 [9878535.001]
  • [Cites] Recent Results Cancer Res. 1998;152:63-70 [9928547.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):299-304 [10188734.001]
  • [Cites] Mol Endocrinol. 1999 May;13(5):787-96 [10319328.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Sep;23(3):385-94 [15595626.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):645-9 [15917419.001]
  • [Cites] J Biol Chem. 2005 Aug 19;280(33):29912-20 [15967802.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2545-54 [11489838.001]
  • (PMID = 16882697.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Estrogen Receptor alpha; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Neoplasm Proteins; 0 / Phosphoproteins
  • [Other-IDs] NLM/ PMC1955087
  •  go-up   go-down


68. Huang W, Zhang Y, Varambally S, Chinnaiyan AM, Banerjee M, Merajver SD, Kleer CG: Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. Am J Pathol; 2008 Apr;172(4):893-904
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.
  • The cysteine-rich protein CCN6 [or Wnt-1-induced signaling protein 3 (WISP3)] exerts tumor-suppressive effects in aggressive inflammatory breast cancer.
  • In vitro, RNA interference knockdown of CCN6 in two benign human mammary epithelial cell lines (HME and MCF10A) decreased expression of E-cadherin protein and mRNA and reduced activity of the E-cadherin promoter; this reduction was dependent on intact E-box elements.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Dec 2;18(51):7274-9 [10602481.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Biotechniques. 2000 Jul;29(1):78-81 [10907080.001]
  • [Cites] Mol Pathol. 2001 Apr;54(2):57-79 [11322167.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):849-59 [11891184.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1613-8 [11912130.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3172-80 [12082632.001]
  • [Cites] Mol Pathol. 2002 Aug;55(4):250-61 [12147716.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29399-405 [12050162.001]
  • [Cites] Semin Cancer Biol. 2002 Oct;12(5):373-9 [12191636.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Mol Pathol. 2003 Apr;56(2):127-8 [12665631.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1445-8 [12670887.001]
  • [Cites] J Biol Chem. 2003 Jun 27;278(26):24200-8 [12695522.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] Breast Cancer Res. 2003;5(6):R217-22 [14580257.001]
  • [Cites] Breast Cancer Res. 2004;6(1):R110-5 [14696649.001]
  • [Cites] Neoplasia. 2004 Mar-Apr;6(2):179-85 [15140407.001]
  • [Cites] Nat Cell Biol. 2004 Oct;6(10):931-40 [15448698.001]
  • [Cites] J Clin Pathol. 1993 Feb;46(2):189-90 [8459046.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14717-22 [9843955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):869-74 [9927660.001]
  • [Cites] Exp Cell Res. 1999 Apr 10;248(1):44-57 [10094812.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2511-9 [10499627.001]
  • [Cites] J Cell Biol. 2005 Jan 3;168(1):29-33 [15631989.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):8229-37 [15611078.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11740-8 [15647282.001]
  • [Cites] Oncogene. 2005 Mar 31;24(14):2375-85 [15674322.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3179-84 [15833848.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1418-23 [15941950.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4349-61 [15824736.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):499-508 [16107313.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):197-209 [16169465.001]
  • [Cites] Breast Cancer Res Treat. 2005 Sep;93(2):101-10 [16187229.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R1080-9 [16457688.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1398-406 [17072303.001]
  • [Cites] FEBS Lett. 2007 Apr 17;581(8):1617-24 [17391671.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • (PMID = 18321996.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA 090876; United States / NCI NIH HHS / CA / R01 CA 66712; United States / NCI NIH HHS / CA / R01 CA 107469; United States / NCI NIH HHS / CA / R01 CA107469; United States / NCI NIH HHS / CA / K08 CA090876
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCN Intercellular Signaling Proteins; 0 / Cadherins; 0 / Homeodomain Proteins; 0 / Insulin-Like Growth Factor Binding Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / WISP3 protein, human; 0 / ZEB1 protein, human; 0 / snail family transcription factors
  • [Other-IDs] NLM/ PMC2276413
  •  go-up   go-down


69. Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL: S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol; 2010 Sep;41(9):1210-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologic distinction between benign and malignant bile duct epithelial lesions on endoscopic biopsies can be extremely challenging because of limited material, crush artifact, and compounding inflammatory and/or reactive changes particularly after stent placement.
  • In this study, a total of 72 endoscopic bile duct biopsies, including 40 adenocarcinomas and 32 benign cases, were immunohistochemically examined for the expression of S100P, von Hippel-Lindau gene product (pVHL), and IMP3 to evaluate their diagnostic value.
  • Intermediate to strong cytoplasmic staining for IMP3 was demonstrated in 31 tumors (77.5%) (15 diffuse, 16 focal).
  • In the remaining 3 tumors, focal (1) or diffuse (2) membranous and cytoplasmic pVHL immunoreactivity was detected.
  • Twenty-eight tumors (70%) showed a S100P+/IMP3+/pVHL- staining pattern, 6 (15%) with a S100P+/IMP3-/pVHL- pattern, and 2 (5%) with a S100P-/IMP3+/pVHL- pattern.
  • All 32 benign biopsies were completely negative for IMP3 with the exception of 2 cases with focal dysplasia where focal immunoreactivity was observed.
  • Thirty benign biopsies (93.8%) were positive for pVHL with a diffuse staining pattern observed in 28 cases (93.3%).
  • Eight benign biopsies (25%) showed focal S100P positivity.
  • Twenty-two benign biopsies (68.8%) displayed a S100P-/IMP3-/pVHL+ staining pattern.
  • In conclusion, an immunohistochemical panel consisting of S100P, pVHL, and IMP3 can be helpful in distinguishing adenocarcinoma from reactive epithelial changes on challenging bile duct biopsies.
  • The findings of focal S100P and/or IMP3 expression with reciprocal loss of pVHL immunoreactivity in a few benign biopsies suggest a use of these markers in the detection of early epithelial dysplasia that may be beyond histologic recognition.
  • [MeSH-major] Adenocarcinoma / diagnosis. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / analysis. Carrier Proteins / analysis. Nuclear Proteins / analysis. RNA-Binding Proteins / analysis. Von Hippel-Lindau Tumor Suppressor Protein / analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Hum Pathol. 2011 Sep;42(9):1368; author reply 1368-9 [21704356.001]
  • (PMID = 20382408.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / IMP3 protein, human; 0 / Nuclear Proteins; 0 / RNA-Binding Proteins; 0 / S100PBP protein, human; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


70. Kato N, Sasou S, Motoyama T: Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol; 2006 Jan;19(1):83-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary.
  • Clear cell tumors of the ovary are frequently associated with ovarian endometriosis.
  • Clinicopathologically, it has been suggested that clear cell tumors develop from endometriosis, but there has been little molecular evidence supporting this speculation.
  • In the present study, we examined 30 clear cell tumors (26 malignant, three borderline, and one benign) and 40 endometriotic cysts to clarify if differentiation into the clear cell lineage already begins in ovarian endometriosis.
  • All of the 30 clear cell tumors, including borderline and benign ones, showed immunohistochemical expression of HNF-1beta in the nucleus, while other types of ovarian epithelial tumors (endometrioid, serous, mucinous, and Brenner tumors) rarely expressed it.
  • Among 30 clear cell tumors, 17 (56%) cases were associated with endometriosis, and endometriotic epithelium was identified in 12 cases.
  • In nine of the 12 cases, distinct nuclear immunostaining for HNF-1beta was detected in the endometriotic epithelium, as well as in the clear cell tumor.
  • HNF-1beta expression was observed either in atypical endometriosis (four cases), or in endometriosis of a reactive nature (five cases).
  • Furthermore, 16 of 40 (40%) endometriotic cysts without a neoplasm also expressed HNF-1beta, and the expression was almost exclusively observed in the epithelium showing inflammatory atypia.
  • Our results indicate that HNF-1beta is an excellent molecular marker for ovarian clear cell tumors, including benign, borderline and malignant lesions.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Hepatocyte Nuclear Factor 1-beta / biosynthesis. Ovarian Diseases / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Ovarian Cysts / metabolism. Ovarian Cysts / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258507.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


71. Shields CL, Shields JA: Conjunctival tumors in children. Curr Opin Ophthalmol; 2007 Sep;18(5):351-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjunctival tumors in children.
  • PURPOSE OF REVIEW: Numerous conjunctival tumors can occur in children, originating from tissues of choristomatous, epithelial, melanocytic, vascular, fibrous, xanthomatous and lymphoid.
  • Overall, 97% prove to be benign and only 3% are malignant.
  • In our experience, the most common conjunctival tumors in children include nevus (64%), dermolipoma (5%), lymphangioma (3%) and capillary hemangioma (3%).
  • SUMMARY: Conjunctival nevus is the most common conjunctival tumor in children and fewer than 1% evolve into melanoma over time.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17700226.001).
  • [ISSN] 1040-8738
  • [Journal-full-title] Current opinion in ophthalmology
  • [ISO-abbreviation] Curr Opin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


72. Altemani A, Martins MT, Freitas L, Soares F, Araújo NS, Araújo VC: Carcinoma ex pleomorphic adenoma (CXPA): immunoprofile of the cells involved in carcinomatous progression. Histopathology; 2005 Jun;46(6):635-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CXPAs were classified into two main groups according to their predominant cellular component as detected by the panel of antibodies: (i) carcinomas with only epithelial differentiation (75% of the cases), and (ii) carcinomas with a myoepithelial component (25%).
  • CXPA with only epithelial differentiation showed two types of malignant areas in the part of the tumour that was confined by the PA capsule: (i) intraductal carcinoma areas characterized by ductal structures containing both benign myoepithelial cells positive for alpha-smooth muscle actin (alpha-SMA), vimentin and cytokeratin (CK)14 and proliferating atypical luminal cells reactive for CK7, CK8 and CK19, and (ii) carcinoma areas composed only of epithelial cells reactive for CK7, CK8 and CK19.
  • CONCLUSION: Most CXPAs consist only of epithelial cells that have an immunoprofile comparable to ductal luminal cells of PA.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Pleomorphic / pathology. Biomarkers, Tumor / analysis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15910594.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / KRT14 protein, human; 0 / KRT7 protein, human; 0 / Keratin-14; 0 / Keratin-7; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


73. Fan SQ, Liang QC, Jiang Y: Thyroid teratoma in an 11-month-old infant. Int J Surg; 2008 Dec;6(6):462-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of congenital benign thyroid teratoma in an 11-month-old male infant who was found to have right thyroid gland mass since birth.
  • The tumor was 25 x 20 x 15 mm with whole thin capsule and could be easily dissected from the surrounding normal thyroid tissue at surgery.
  • Histologically, tumor had mature derivatives of the three primordial germ layers with a variety of benign and well-differentiated elements.
  • It was the most conspicuous feature that the tumor was composed mainly of the neurological tissue resembling brain tissue with glial cells and ependymal epithelium components.
  • There were a few anastomosing variably sized tubules and cysts lined by ependymal epithelial cells with papillary feature and retinal pigment epithelial cells.
  • In summary, benign teratoma of thyroid gland in an 11-month-old infant was morphologically and immunophenotypically identified.

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19059145.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Saba CF, Rogers KS, Newman SJ, Mauldin GE, Vail DM: Mammary gland tumors in male dogs. J Vet Intern Med; 2007 Sep-Oct;21(5):1056-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary gland tumors in male dogs.
  • BACKGROUND: Reports of mammary-gland tumors in male dogs are lacking.
  • OBJECTIVE: To describe the clinical characteristics of mammary-gland tumors in male dogs.
  • ANIMALS: Eight male dogs diagnosed with mammary-gland tumors.
  • RESULTS: Eight dogs with histologically confirmed mammary-gland tumors were included in this retrospective study.
  • Mammary-gland tumors were incidental findings in 7 of 8 dogs.
  • All but 1 dog had benign epithelial tumors.
  • The dog with the malignant tumor was the only dog to develop possible local recurrence but de novo tumor development cannot be excluded.
  • Based on institutional population data, it was determined that female dogs are 62 times more likely to develop mammary-gland tumors than male dogs (P < .001).
  • Estrogen-receptor expression was strong in the majority of tumors; progesterone-receptor expression, although present in all tumors, was less intense.
  • CONCLUSIONS/CLINICAL IMPORTANCE: This study suggests that mammary-gland tumors in male dogs are rare, usually benign, and surgery alone can provide long-term control in most dogs.

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17939564.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


75. Lee WA: Mucinous cystadenoma of the pancreas with predominant stroma creating a solid tumor. World J Surg Oncol; 2005 Sep 7;3:59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous cystadenoma of the pancreas with predominant stroma creating a solid tumor.
  • BACKGROUND: Mucinous cystic neoplasm (MCN) of the pancreas is basically cystic epithelial neoplasm, unilocular or multilocular, occurring almost exclusively in women.
  • CONCLUSION: This case of mucinous cystadenoma of the pancreas showed very interesting pathology: It was solid rather than cystic, and accompanied by abundant benign transitional epithelia, which was a very unusual and novel finding in the mucinous cystic neoplasm of the pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):86-91 [10658914.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):31-42 [10721805.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):66-80 [10721808.001]
  • [Cites] Verh Dtsch Ges Pathol. 2001;85:219-28 [11894402.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(1):116-9 [12021906.001]
  • [Cites] Pathol Int. 1997 Nov;47(11):806-8 [9413043.001]
  • [Cites] Int J Gynecol Pathol. 1993 Apr;12(2):128-33 [8463036.001]
  • [Cites] Obstet Gynecol. 1979 Nov;54(5):660-3 [503400.001]
  • [Cites] Cancer. 1979 May;43(5):1830-9 [445369.001]
  • [Cites] Pathologica. 1989 Jul-Aug;81(1074):381-401 [2696922.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):148-52 [15354741.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Apr;19(4):467-70 [15012791.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):1-16 [9888699.001]
  • (PMID = 16146567.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1236970
  •  go-up   go-down


76. Szajda SD, Jankowska A, Zwierz K: Carbohydrate markers in colon carcinoma. Dis Markers; 2008;25(4-5):233-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spontaneously mutated multiple oncogenes and/or tumor suppressor genes in colon epithelial cell and its progeny, may cause proliferation out of control and create benign colon neoplasm (colon polyp).
  • If additional mutations involve genes responsible for cell adhesion and movement, aberrant epithelial cells may become malignant (colon cancer) and invade surrounding and remote tissues, creating secondary tumors called metastases.
  • To laboratory detection and monitoring of colon cancer are used tumor markers.
  • Tumor markers are substances produced by the body in response to cancer, or by cancer tissue itself.
  • Glycoconjugate markers for colon cancer include aberrant: mucins covering the surface of the colon epithelial cells, cadherins, selectins and Ig-like adhesion molecules mediating cell-cell adhesion, integrins and integral membrane proteoglycans responsible for adhesion of colon epithelial cells to extracellular matrix, glycoconjugate components of ECM, as well as lysosomal membrane glycoproteins and exoglycosidases.
  • A glycobiological approach to diagnosis and treatment of colorectal cancer should be directed to detection changes in glycosylation accompanying every step of colon cancer progression, and correlation between changes in glycosylation and tumor progression.
  • [MeSH-minor] Aged. Cadherins / chemistry. Cell Adhesion. Disease Progression. Epithelial Cells / metabolism. Glycoproteins / chemistry. Glycoproteins / metabolism. Humans. Middle Aged. Mucins / metabolism. Neoplasm Invasiveness. Neoplasm Metastasis. Polysaccharides / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126967.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / Carbohydrates; 0 / Glycoproteins; 0 / Mucins; 0 / Polysaccharides
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC3827819
  •  go-up   go-down


77. Kurjak A, Prka M, Arenas JM, Sparac V, Merce LT, Corusic A, Ivancic-Kosuta M: Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic peri- and postmenopausal women. Croat Med J; 2005 Oct;46(5):757-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Any multiloculated, complex or solid ovarian mass, as well as persistently cystic mass >5 cm in diameter, in which the echo architecture and/or blood flow pattern was not highly suggestive of a benign histology, was categorized malignant.
  • After detailed ultrasonographic examination, surgical removal of the tumor and pathohistological classification were completed.
  • RESULTS: Twenty-five patients (0.8%) with persisting ultrasonographic abnormalities after primary and secondary screening underwent surgery to remove the ovarian tumor.
  • Five epithelial ovarian cancers were detected: 3 stage IA, 1 stage IB, and 1 stage IC.
  • Three stage I patients had a palpable abnormality on clinical examination.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158468.001).
  • [ISSN] 0353-9504
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


78. Daneshbod Y, Khademi B, Moemeni B, Seif I, Daneshbod K: Preoperative washing cytology in the diagnosis of maxillary sinus lesions. Acta Cytol; 2010 Mar-Apr;54(2):148-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Over a 4-year period, 96 p tients with clinical or radiologic suspicion of a malignant maxillary sinus tumor either confined to the maxillary complex or extending to the nasal cavity underwent preoperative cytologic evaluation by sinus puncture and local washing or nasal washing.
  • RESULTS: There were 47 malignant, 42 benign and 7 borderline cases.
  • Benign lesions included inflammatory conditions (17), squamous proliferations (6), soft tissue lesions (9) and odontogenic lesions (10).
  • Malignant lesions included squamous cell carcinoma (8), sinonasal adenocarcinoma (2), salivary gland tumors (4), soft tissue tumors (18), malignant melanoma (8) and hematolymphoid neoplasms (7).
  • Diagnostic agreement between cytology and follow-up biopsy was seen mostly in benign inflammatory and odontogenic lesions and in squamous cell carcinoma and salivary gland malignancies.
  • Clusters of sloughed epithelial cells, so called Creola bodies, may be a diagnostic pitfall in benign lesions.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391970.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Melichar B, Solichová D, Freedman RS: Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):240-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant tumors may contribute to host response that involves both the adaptive and innate immune systems.
  • In addition to tumors of other primary locations, increased urinary and serum neopterin concentrations have been reported in patients with gynecological cancers, including epithelial ovarian carcinoma, cervical carcinoma, endometrial carcinoma, uterine sarcomas, and vulvar carcinoma, but not in women with benign neoplasms or precancerous disorders.
  • Elevated levels of neopterin have also been observed in the tumor microenvironment.
  • [MeSH-minor] Adult. Aged. Biomarkers / analysis. Endometrial Neoplasms / immunology. Endometrial Neoplasms / mortality. Endometrial Neoplasms / pathology. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / immunology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Prognosis. Sensitivity and Specificity. Survival Analysis. Treatment Outcome. Uterine Cervical Neoplasms / immunology. Uterine Cervical Neoplasms / mortality. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445639.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 670-65-5 / Neopterin
  • [Number-of-references] 134
  •  go-up   go-down


80. Markert E, Gruber-Moesenbacher U, Porubsky C, Popper HH: Lung osteoma--a new benign lung lesion. Virchows Arch; 2006 Jul;449(1):117-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung osteoma--a new benign lung lesion.
  • Tumors with osseous elements can be found, such as hamartoma and amyloid tumor, and reactive lesions such as osseous metaplasia.
  • A 39-year-old male patient was treated for multiple myeloma and got a bone marrow transplantation 2 years and a few months before he presented with a solitary well-circumscribed tumor in the right middle lobe.
  • The tumor presented with a fibrous capsule and consisted of mature bone trabecules.
  • Within the tumor, fatty tissue was seen.
  • No amyloid deposition, no immature epithelial tubules as in hamartomas, and no normal lung structure as in osseous metaplasia were seen.
  • This tumor might have been induced by circulating stem cells; however, due to autologous bona marrow transplantation, this cannot be proven.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Bone Marrow Transplantation. Diagnosis, Differential. Hamartoma / diagnosis. Humans. Immunohistochemistry. Male. Multiple Myeloma / pathology. Multiple Myeloma / therapy. Osteonectin / analysis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust Vet J. 1984 Dec;61(12):405-7 [6534360.001]
  • [Cites] Exp Hematol. 1983 Nov;11(10):961-6 [6420177.001]
  • [Cites] Eur J Cardiothorac Surg. 1990;4(1):15-8 [2407277.001]
  • [Cites] J Thorac Cardiovasc Surg. 1992 Sep;104(3):674-8 [1513155.001]
  • [Cites] Am J Ophthalmol. 1982 Feb;93(2):192-7 [6978070.001]
  • [Cites] Ear Nose Throat J. 1997 Nov;76(11):827-8 [9397630.001]
  • [Cites] Respiration. 1981;42(2):129-34 [7313332.001]
  • [Cites] Hematol Oncol Clin North Am. 1989 Jun;3(2):303-18 [2663829.001]
  • [Cites] Thorax. 1987 Oct;42(10):790-3 [3321538.001]
  • [Cites] Diagn Cytopathol. 1993 Oct;9(5):570-5 [8287770.001]
  • [Cites] Orthop Clin North Am. 1996 Jul;27(3):559-74 [8649737.001]
  • [Cites] Mayo Clin Proc. 1996 Jan;71(1):14-20 [8538225.001]
  • (PMID = 16639606.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Osteonectin
  •  go-up   go-down


81. Ohe C, Sakaida N, Yanagimoto Y, Toyokawa H, Satoi S, Kwon AH, Tadokoro C, Takasu K, Uemura Y: A case of splenic low-grade mucinous cystadenocarcinoma resulting in pseudomyxoma peritonei. Med Mol Morphol; 2010 Dec;43(4):235-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopically, splenic parenchyma was occupied by large mucinous pools focally lined with mucinous epithelial cells and mesothelial cell-like cells, which were considered benign.
  • Although most PMP cases are known to be caused by low-grade mucinous appendiceal tumor, the present case represents the first report of a splenic MCCa resulting in PMP.

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Jul;14(7):793-6 [12169992.001]
  • [Cites] Tumori. 1998 Sep-Oct;84(5):606-10 [9862526.001]
  • [Cites] Am J Clin Pathol. 1981 Nov;76(5):666-9 [7293981.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Jul;16(7):825-9 [11446896.001]
  • [Cites] South Med J. 1989 Aug;82(8):1029-31 [2548288.001]
  • [Cites] Lijec Vjesn. 2000 Nov-Dec;122(11-12):272-5 [11291270.001]
  • [Cites] Histopathology. 1999 Dec;35(6):551-7 [10583579.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):903-8 [1415909.001]
  • [Cites] Chest. 1977 Dec;72(6):792-4 [923321.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1997 Nov;94(11):757-61 [9396331.001]
  • [Cites] Semin Diagn Pathol. 2006 Feb;23(1):20-4 [17044192.001]
  • [Cites] Trop Gastroenterol. 1991 Oct-Dec;12 (4):195-8 [1814031.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):359-67 [15725805.001]
  • [Cites] Acta Pathol Jpn. 1981 Nov;31(6):1089-96 [7315312.001]
  • [Cites] Dig Dis Sci. 1999 Apr;44(4):768-74 [10219836.001]
  • [Cites] Surgery. 1976 Nov;80(5):652-4 [982285.001]
  • [Cites] Int J Clin Oncol. 2006 Oct;11(5):416-9 [17058142.001]
  • (PMID = 21267701.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Soini Y, Talvensaari-Mattila A: Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types. Int J Gynecol Pathol; 2006 Oct;25(4):330-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types.
  • Strong expression of claudins 1, 4, and 7 was seen in benign and malignant epithelial ovarian tumors.
  • Expression of claudin 5, reported to be mainly present in endothelial cells, was seen in ovarian epithelial tumors, but with a significantly lower frequency than claudins 1, 4, and 7.
  • On the contrary, sex-cord stromal tumors and cysts, such as fibromas/thecomas, Sertoli-Leydig cell tumors, granulosa cell tumors, and follicular and luteinized cysts were mainly negative for claudins 1, 4, 5, and 7.
  • Interestingly, adenomatoid tumors did not express claudin 5, which is in agreement with their non-endothelial nature.
  • They were also negative for claudin 4, but expressed claudins 1 and 7, but to a lesser degree than epithelial lesions.
  • In immature teratomas, the epithelial component was usually positive whereas other components were negative for these claudins.
  • The results show that claudins 1, 4, and 7 are mainly expressed in ovarian epithelial tumors and can thus be used to indicate epithelial differentiation in them.
  • Eventhough considered an endothelial marker, claudin 5 was also present in a subset of epithelial lesions.
  • However, this claudin can be used to differentiate adenomatoid tumors from vascular lesions.
  • No significant difference was seen between epithelial benign and malignant lesions, except for claudin 5, which seemed stronger in malignant epithelial tumors.
  • [MeSH-minor] Adenomatoid Tumor / chemistry. Brenner Tumor / chemistry. Carcinoma / chemistry. Claudin-1. Claudin-4. Claudin-5. Claudins. Dysgerminoma / chemistry. Female. Humans. Immunohistochemistry. Krukenberg Tumor / chemistry. Ovarian Cysts. Sex Cord-Gonadal Stromal Tumors / chemistry. Teratoma / chemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990707.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / CLDN5 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Claudin-5; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


83. Sliwińska-Mossoń M, Milnerowicz H, Rabczyński J, Milnerowicz S: Immunohistochemical localization of metallothionein and p53 protein in pancreatic serous cystadenomas. Arch Immunol Ther Exp (Warsz); 2009 Jul-Aug;57(4):295-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Neoplastic pancreatic tissue was taken from 20 patients with diagnosed benign (SCA: 5 cases) or malignant tumors (adenomocarcinomas: 15 cases) and control pancreatic tissue from healthy persons who had died in car accidents.
  • RESULTS: Metallothionein expression was observed only in the epithelial cells of the neoplastic tissue of SCAs.
  • Increased expressions of MT and p53 were observed in the less differentiated tumors.
  • Thus the expression of MT may be a potential prognostic marker for tumors.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Cystadenoma, Serous / pathology. Metallothionein / metabolism. Pancreatic Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19578815.001).
  • [ISSN] 1661-4917
  • [Journal-full-title] Archivum immunologiae et therapiae experimentalis
  • [ISO-abbreviation] Arch. Immunol. Ther. Exp. (Warsz.)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; 9038-94-2 / Metallothionein
  •  go-up   go-down


84. Coston WM, Loera S, Lau SK, Ishizawa S, Jiang Z, Wu CL, Yen Y, Weiss LM, Chu PG: Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol; 2008 Mar;32(3):433-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
  • Distinguishing a well-differentiated hepatocellular carcinoma (HCC) from normal and cirrhotic liver tissue or benign liver nodules, such as hepatic adenoma (HA) and focal nodular hyperplasia (FNH), may be very difficult in some cases, particularly in small needle core biopsies.
  • In addition, we studied GPC3 expression in 225 cases of nonhepatic human tumors with epithelial differentiation.
  • Ninety-four of 107 cases (88%) of HCC showed focal or diffuse cytoplasmic GPC3 staining, whereas all HA and FNH cases were GPC3-negative, and only 7 of 225 cases (3%) of nonhepatic tumors with epithelial differentiation expressed GPC3.
  • We conclude that GPC3 is a very specific marker not only for differentiating HCC from nonhepatic tumors with epithelial differentiation, but also for differentiating HCC from HA and FNH.
  • GPC3 immunoreactivity, in combination with a complete CD34 immunostaining pattern, greatly facilitates the accuracy of distinguishing between malignant hepatic lesions and benign mimickers.
  • [MeSH-minor] Adenoma / chemistry. Biomarkers, Tumor / analysis. Humans. Hyperplasia. Immunohistochemistry. Liver / chemistry. Liver / pathology. Liver Diseases / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300806.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Glypicans
  •  go-up   go-down


85. Shi HR, Zhang RT: [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer]. Ai Zheng; 2009 Aug;28(8):882-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer].
  • This study was to investigate the expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer.
  • METHODS: The expression of P53, P21WAF1 and CDK1 proteins in 20 specimens of normal ovarian tissues, 20 specimens of benign epithelial ovarian tumor and 76 specimens of epithelial ovarian cancer was detected by immunohistochemistry.
  • Their correlations to the clinicopathologic characteristics of epithelial ovarian cancer and their interrelationships were analyzed.
  • RESULTS: Significant differences were noted in the positive rates of P53, P21WAF1 and CDK1 proteins between epithelial ovarian cancer and normal ovarian tissues, benign ovarian tumors (P < 0.05).
  • In epithelial ovarian cancer, up-regulation of P53 protein was associated with advanced FIGO stage and poor differentiation; down-regulation of P21WAF1 protein was associated with advanced FIGO stage; CDK1 showed no association with any clinicopathologic factors.
  • CONCLUSIONS: P53 protein is related to the malignancy of epithelial ovarian cancer, P53 and P21WAF1 protein may be related to the malignant development of epithelial ovarian cancer.
  • CDK1 detection may be helpful in the early diagnosis of epithelial ovarian cancer.
  • [MeSH-major] CDC2 Protein Kinase / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664338.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.11.22 / CDC2 Protein Kinase
  •  go-up   go-down


86. Singh R, Browning JL, Abi-Habib R, Wong K, Williams SA, Merchant R, Denmeade SR, Buckley TJ, Frankel AE: Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anticancer Drugs; 2007 Aug;18(7):809-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most normal human cells with the exception of prostate and renal epithelial cells showed very low sensitivity to recombinant modified proaerolysin.
  • Our results suggest that recombinant modified proaerolysin is a potent prostate-specific antigen-sensitive protoxin that deserves further development for regional therapy of benign and malignant prostate growths.
  • [MeSH-minor] Aeromonas salmonicida / chemistry. Cell Line, Tumor. Chromatography, High Pressure Liquid. Drug Delivery Systems. Drug Screening Assays, Antitumor. Electrophoresis, Polyacrylamide Gel. Genetic Engineering. Humans. Male. Peptide Hydrolases / metabolism. Prodrugs

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581303.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bacterial Toxins; 0 / PRX302; 0 / Pore Forming Cytotoxic Proteins; 0 / Prodrugs; EC 3.4.- / Peptide Hydrolases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


87. Pasternak S, MacIntosh R: Uterine adenosarcoma detected by Papanicolaou smear: a case report. Diagn Cytopathol; 2006 Jul;34(7):495-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenosarcoma is a rare uterine biphasic tumor composed of benign epithelial elements and a sarcomatous stroma.

  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16783778.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Nakano K, Siar CH, Tsujigiwa H, Nagatsuka H, Nagai N, Kawakami T: Notch signaling in benign and malignant ameloblastic neoplasms. Eur J Med Res; 2008 Oct 27;13(10):476-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch signaling in benign and malignant ameloblastic neoplasms.
  • METHODS: We examined Notch1 peptide and its gene (mRNA) in an ameloblastoma (case 1: 27-year-old female, right mandibular tumor) and an ameloblastic carcinoma (case 2: 93-year-old female, right mandibular tumor), using immunohistochemistry (IHC) and in situ hybridization (ISH) techniques.
  • RESULTS: Notch1 intracellular domain (NICD) positive products were observed in the cells at the peripheral layer of most proliferating epithelial tumor nests in case 1.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression. Humans. Immunohistochemistry. In Situ Hybridization. Protein Structure, Tertiary. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19008176.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / NOTCH1 protein, human; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptor, Notch1
  •  go-up   go-down


89. Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB: MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol; 2010 Sep;118(3):251-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA signatures differentiate uterine cancer tumor subtypes.
  • METHODS: Ninety-five fresh/frozen and paraffin-embedded samples of endometrial type I and II cancer, carcinosarcomas and benign endometrial samples were collected.
  • RESULTS: Distinct miRNA signatures in tumor versus normal samples and in endometrioid vs. uterine papillary serous carcinomas exist.
  • Additionally, carcinosarcomas have a unique miRNA signature from either the type I or II epithelial tumors.
  • CONCLUSIONS: We hypothesize that further understanding the miRNAs that separate these subtypes of EC will lead to biological insights into the different behavior of these tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Gynecol Oncol. 2000 Apr;77(1):1-7 [10739683.001]
  • [Cites] Nat Cell Biol. 2010 Apr;12(4):372-9 [20190740.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):687-90 [12445244.001]
  • [Cites] Hokkaido Igaku Zasshi. 2003 Mar;78(2):117-27 [12704854.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2003 Aug;32(4):314-8 [14514374.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5675-82 [14654551.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] Am J Clin Pathol. 1982 May;77(5):534-40 [7081149.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):93-108 [7102898.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer. 1983 May 1;51(9):1705-9 [6831367.001]
  • [Cites] Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):15-21 [1670908.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3093-103 [2044053.001]
  • [Cites] Gynecol Oncol. 1992 Dec;47(3):298-305 [1473741.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4667-70 [8062261.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):264-8 [8088602.001]
  • [Cites] Obstet Gynecol. 1995 May;85(5 Pt 1):729-34 [7724103.001]
  • [Cites] N Engl J Med. 1996 Aug 29;335(9):640-9 [8692240.001]
  • [Cites] J Soc Gynecol Investig. 1996 May-Jun;3(3):99-105 [8796816.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3935-40 [9307275.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):821-7 [9311600.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):70-5 [9345359.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):253-7 [9648597.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Future Oncol. 2006 Feb;2(1):73-82 [16556074.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1812-20 [17071602.001]
  • [Cites] Rom J Morphol Embryol. 2006;47(2):137-41 [17106521.001]
  • [Cites] PLoS One. 2006;1:e116 [17205120.001]
  • [Cites] DNA Cell Biol. 2007 May;26(5):283-92 [17504024.001]
  • [Cites] DNA Cell Biol. 2007 May;26(5):293-300 [17504025.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5699-707 [17575136.001]
  • [Cites] Urol Oncol. 2007 Sep-Oct;25(5):387-92 [17826655.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8699-707 [17875710.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Feb;135(2):255-60; discussion 260 [18242245.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Oncogene. 2008 Mar 13;27(12):1788-93 [17891175.001]
  • [Cites] Genes Dev. 2008 Apr 1;22(7):894-907 [18381893.001]
  • [Cites] Vopr Onkol. 2007;53(6):682-9 [18416138.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9 [18458333.001]
  • [Cites] FEBS Lett. 2008 Oct 29;582(25-26):3663-8 [18840437.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1135-42 [19155302.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1814-9 [19188590.001]
  • [Cites] Int J Cancer. 2009 May 1;124(9):2236-42 [19127597.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2287-95 [19244118.001]
  • [Cites] PLoS One. 2009;4(10):e7629 [19893619.001]
  • [Cites] Genes Dev. 2009 Dec 15;23(24):2839-49 [20008935.001]
  • [Cites] Cancer Res. 2010 Mar 1;70(5):1916-24 [20160038.001]
  • [Cites] J Biomed Biotechnol. 2010;2010:369549 [20300586.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):321-5 [11986333.001]
  • (PMID = 20542546.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA124484-01A1; United States / NCI NIH HHS / CA / K08 CA124484; United States / NIDDK NIH HHS / DK / P30 DK072442; United States / NCI NIH HHS / CA / K08 CA124484-01A1; United States / NCI NIH HHS / CA / U10 CA021661; United States / NCI NIH HHS / CA / U10CA21661
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS208098; NLM/ PMC2918705
  •  go-up   go-down


90. Moslemi MK: Mixed epithelial and stromal tumor of the kidney or adult mesoblastic nephroma: an update. Urol J; 2010;7(3):141-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed epithelial and stromal tumor of the kidney or adult mesoblastic nephroma: an update.
  • PURPOSE: Our aim was to review the spectrum of usual and unusual clinical and morphologic findings observed in mixed epithelial and stromal tumor of the kidney (MEST).
  • RESULTS: Mixed epithelial and stromal tumor is a relatively rare and distinct neoplasm of the kidney that should be distinguished from other renal neoplasms.
  • Although the overall prognosis is favorable, recurrence and malignant transformation of MEST can occur CONCLUSION: It is difficult to distinguish benign or malignant nature on imaging studies.


91. Sato K, Ueda Y, Shimasaki M, Ozaki M, Nitta N, Chada K, Ishikawa Y, Katsuda S: Pleomorphic adenoma (benign mixed tumor) of the breast: a case report and review of the literature. Pathol Res Pract; 2005;201(4):333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma (benign mixed tumor) of the breast: a case report and review of the literature.
  • We report a case of pleomorphic adenoma (benign mixed tumor) of the breast, which is an extremely rare location for this tumor.
  • Examination of a 55-year-old woman unexpectedly revealed a mass measuring 0.8 cm in diameter in the subareolar region of the right breast.
  • Excisional biopsy was performed, and the tumor histologically showed pleomorphic adenoma composed of duct epithelial cells, myoepithelial cells, and a myxochondroid matrix.
  • Immunohistochemically, duct epithelial cells were positive for the estrogen receptor, but negative for the progesterone receptor.
  • Sixty-nine cases of this type of tumor arising in the breast have been described previously.
  • Using imaging procedures, the tumor has occasionally been misdiagnosed as malignant clinically and even pathologically in frozen section diagnosis.
  • Careful diagnosis based on paraffin sections is required to avoid unnecessary aggressive surgery, and pathologists should include pleomorphic adenoma in the differential diagnosis of a demarcated, juxtaareolar, small hard mass.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. HMGA1a Protein / analysis. HMGA2 Protein / analysis. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Middle Aged. Receptors, Estrogen / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991841.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HMGA2 Protein; 0 / Receptors, Estrogen; 124544-67-8 / HMGA1a Protein
  • [Number-of-references] 32
  •  go-up   go-down


92. Aikhionbare FO, Mehrabi S, Kumaresan K, Zavareh M, Olatinwo M, Odunsi K, Partridge E: Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages. J Carcinog; 2007 Jan 26;6:1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages.
  • BACKGROUND: A majority of primary ovarian neoplasms arise from cell surface epithelium of the ovaries.
  • Although old age and a positive family history are associated risk factors, the etiology of the epithelial ovarian tumors is not completely understood.
  • Additionally, knowledge of factors involved in the histogenesis of the various subtypes of this tumor as well as those factors that promote progression to advanced stages of ovarian malignancy are largely unknown.
  • METHODS: In this study, we determined the presence of polymorphisms and other sequence variants of mitochondrial DNA (mtDNA) in 102 epithelial ovarian tumors including 10 matched normal tissues that paired with some of the tumors.
  • There were relatively high frequencies of three mutations in the 12S rRNA gene at np 772, 773, and 780 in stage IIIC endometrioid tumors, two of which are novel (773delT and 780delC), and occurred with a frequency of 100% (7/7).
  • Furthermore, two mutations were observed in serous tumors only at np 1657 in stage IV (10/10), and at np 8221delA in benign cystadenomas (3/3) and borderline tumors (4/4).
  • A high frequency, 81% (13/16) of TC insertion at np 310 was found only in early stages of serous subtype (benign cystadenomas, 3/3; borderline tumors, 4/4; stage I tumors, 2/5 and matched normal tissues 4/4).
  • CONCLUSION: Our findings indicate that certain mtDNA mutations can reliably distinguish the different histologic subtypes of epithelial ovarian tumors.
  • In addition, these data raise the possibility that certain mtDNA mutations may be useful biomarkers for predicting tumor aggressiveness and may play a potential role in tumorigenesis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24 [15647368.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):291-3 [9806551.001]
  • [Cites] Biochim Biophys Acta. 1999 Feb 9;1410(2):103-23 [10076021.001]
  • [Cites] Eur J Cancer. 1999 Feb;35(2):316-9 [10448277.001]
  • [Cites] Mutat Res. 1999 Jul 30;434(3):177-203 [10486591.001]
  • [Cites] Science. 2000 Mar 17;287(5460):2017-9 [10720328.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4231-7 [10945635.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5007-11 [11016619.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1843-5 [11280735.001]
  • [Cites] Mutat Res. 2001 May;488(2):119-33 [11344040.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38555-62 [11504725.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5998-6001 [11507041.001]
  • [Cites] Am J Kidney Dis. 2001 Sep;38(3):529-36 [11532685.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7015-9 [11585726.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7623-6 [11606403.001]
  • [Cites] J Hum Genet. 2002;47(3):122-30 [11950064.001]
  • [Cites] Nucleic Acids Res. 2002 Jul 1;30(13):2817-24 [12087165.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2260-5 [12114429.001]
  • [Cites] J Pathol. 2003 Feb;199(2):237-42 [12533837.001]
  • [Cites] Cancer Lett. 2003 Feb 10;190(1):73-7 [12536079.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1838-43 [12578990.001]
  • [Cites] J Surg Oncol. 2003 Mar;82(3):170-3 [12619060.001]
  • [Cites] Hum Mutat. 2003 Apr;21(4):441-3 [12655558.001]
  • [Cites] Genetics. 1992 Jan;130(1):153-62 [1346260.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1314-20 [14647457.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):99-105 [14999140.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4466-77 [15016645.001]
  • [Cites] Mol Cancer Res. 2004 Aug;2(8):433-41 [15328370.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:30 [15482594.001]
  • [Cites] BMC Cancer. 2006;6:21 [16433919.001]
  • [Cites] Mutat Res. 2006 Mar 20;595(1-2):42-51 [16472830.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:259-66 [16515601.001]
  • [Cites] Hum Pathol. 1991 Aug;22(8):750-62 [1869263.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:208-18 [8747398.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):514-9 [9012815.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • (PMID = 17257433.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / P20 MD000272
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC1794240
  •  go-up   go-down


93. Dafou D, Grun B, Sinclair J, Lawrenson K, Benjamin EC, Hogdall E, Kruger-Kjaer S, Christensen L, Sowter HM, Al-Attar A, Edmondson R, Darby S, Berchuck A, Laird PW, Pearce CL, Ramus SJ, Jacobs IJ, Gayther SA: Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia; 2010 Jul;12(7):579-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers.
  • We used a functional complementation approach to identify tumor-suppressor genes and putative therapeutic targets for ovarian cancer.
  • Immunoblot analysis showed that EPB41L3 was activated in TOV21G(+18) hybrids, expressed in normal ovarian epithelial cell lines, but was absent in 15 (78%) of 19 ovarian cancer cell lines.
  • Using immunohistochemistry, 66% of 794 invasive ovarian tumors showed no EPB41L3 expression compared with only 24% of benign ovarian tumors and 0% of normal ovarian epithelial tissues.
  • EPB41L3 was extensively methylated in ovarian cancer cell lines and primary ovarian tumors compared with normal tissues (P = .00004), suggesting this may be the mechanism of gene inactivation in ovarian cancers.
  • [MeSH-major] Chromosomes, Human, Pair 18 / genetics. Gene Transfer Techniques. Membrane Proteins / physiology. Neoplasms, Glandular and Epithelial / genetics. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Apoptosis / genetics. Cell Culture Techniques. Cells, Cultured. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor / physiology. Genetic Association Studies. Humans. Hybrid Cells / metabolism. Hybrid Cells / pathology. Microarray Analysis. Microfilament Proteins. Spheroids, Cellular / metabolism. Spheroids, Cellular / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biotechnol Bioeng. 2003 Jul 20;83(2):173-80 [12768623.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):417-23 [12543797.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8648-55 [14695176.001]
  • [Cites] Nat Genet. 2004 Jan;36(1):40-5 [14702039.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3957-71 [15082789.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jul;40(3):190-203 [15138999.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jul;40(3):247-60 [15139003.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Mar;75(3):1466-9 [274733.001]
  • [Cites] Somatic Cell Genet. 1981 Nov;7(6):699-712 [7323948.001]
  • [Cites] Mol Cell Biol. 1985 Jan;5(1):140-6 [3982414.001]
  • [Cites] Cytogenet Cell Genet. 1995;71(1):68-76 [7606932.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1545-51 [10102624.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Oncogene. 2005 Jan 27;24(5):869-79 [15580292.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 8;329(2):522-30 [15737618.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2954-61 [15837747.001]
  • [Cites] Int J Mol Med. 2005 Oct;16(4):771-4 [16142420.001]
  • [Cites] Genetics. 2005 Oct;171(2):783-90 [15956674.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(22):10052-9 [16260618.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):545-51 [16125217.001]
  • [Cites] Breast Cancer Res Treat. 2005 Dec;94(3):225-35 [16258702.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):220-30 [16281261.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):916-23 [16152585.001]
  • [Cites] BMC Bioinformatics. 2006;7:264 [16716215.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9682-90 [17018626.001]
  • [Cites] Mol Ther. 2006 Dec;14(6):872-82 [16904943.001]
  • [Cites] Mol Cancer. 2007;6:14 [17280610.001]
  • [Cites] Int J Gynecol Pathol. 2007 Apr;26(2):141-6 [17413980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12784-9 [17640904.001]
  • [Cites] Cell Prolif. 2007 Oct;40(5):780-94 [17877616.001]
  • [Cites] Mol Carcinog. 2007 Oct;46(10):819-23 [17415786.001]
  • [Cites] Mol Cancer. 2006;5:4 [16420693.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2489-97 [18381458.001]
  • [Cites] N Engl J Med. 2008 Apr 3;358(14):1454-64 [18385497.001]
  • [Cites] Mol Cancer Res. 2008 Apr;6(4):592-603 [18403638.001]
  • [Cites] RNA. 2008 May;14(5):878-87 [18369183.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):401-8 [18449890.001]
  • [Cites] Pathology. 2008 Aug;40(5):487-92 [18604735.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4372-7 [18628450.001]
  • [Cites] Expert Rev Mol Med. 2008;10:e22 [18671886.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1529-38 [18528427.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16719-24 [18940925.001]
  • [Cites] Biosci Rep. 2008 Dec;28(6):319-26 [18666890.001]
  • [Cites] Int J Cancer. 2009 Mar 1;124(5):1037-44 [19058220.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):234-9 [19136951.001]
  • [Cites] Cell Prolif. 2009 Apr;42(2):219-28 [19222485.001]
  • [Cites] Hum Mol Genet. 2009 May 15;18(10):1869-78 [19270026.001]
  • [Cites] Cell Prolif. 2009 Jun;42(3):385-93 [19397591.001]
  • [Cites] Genome Res. 2000 Dec;10(12):1878-89 [11116084.001]
  • [Cites] Oncogene. 2000 Dec 14;19(54):6277-85 [11175342.001]
  • [Cites] Oncogene. 2001 Jan 18;20(3):314-9 [11313960.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):131-7 [11566343.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Oct 15;130(2):118-26 [11675132.001]
  • [Cites] Genes Chromosomes Cancer. 2002 May;34(1):97-103 [11921287.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):145-55 [12086873.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):181-8 [12115567.001]
  • [Cites] Nature. 2003 Dec 4;426(6966):570-4 [14654843.001]
  • (PMID = 20651987.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0801875; United States / NCI NIH HHS / CA / R01 CA096958
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2907584
  •  go-up   go-down


94. Chen WH, Cheng SP, Tzen CY, Yang TL, Jeng KS, Liu CL, Liu TP: Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol; 2005 Sep 1;91(3):185-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases.
  • BACKGROUND AND OBJECTIVES: Phyllodes tumors (PTs) are uncommon biphasic breast tumors that usually occur in adult females.
  • They are composed of a benign epithelial component and a cellular, spindle cell stroma forming a leaf-like structure.
  • No one morphologic finding is reliable in predicting the clinical behavior of the tumor.
  • Clinical data analyzed included age, presenting symptoms and signs, tumor size, location, type of surgery, time to recurrence, and metastasis.
  • The majority of tumors were found in the upper outer quadrant (46.0%), with an equal propensity to occur in either breast (48.8% vs. 50.0%).
  • The pathologic diagnoses included 131 benign, 12 borderline, and 29 malignant lesions.
  • The initial diagnosis of all 19 recurrent tumors were benign.
  • Stromal cellularity, stromal overgrowth, stromal atypia, mitotic activity, tumor margin, and heterologous stromal elements were significantly correlated with metastases (P = 0.032, 0.00008, 0.000002, 0.004, 0.005, and 0.046, respectively).
  • The reasons for these procedures included a diagnosis of malignancy on frozen section or because the tumors were so large, they were assumed to be carcinomas.
  • Fifteen patients in our series had tumors with infiltrating tumor margin, severe stromal overgrowth, atypia, and cellularity.
  • Patients have tumors with infiltrating tumor margin, severe stromal overgrowth, atypia, and cellularity are at high risk for metastases.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy / methods. Phyllodes Tumor / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Taiwan / epidemiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16118768.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Laco J, Simáková E, Svobodová J, Ryska A: Recurrent mucinous carcinoma of skin mimicking primary mucinous carcinoma of parotid gland: a diagnostic pitfall. Cesk Patol; 2009 Jul;45(3):79-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of a 63-year-old man with a swelling lasting 2 years in the left infraauricular area is reported.
  • The lateral parotidectomy specimen showed a poorly circumscribed gelatinous tumor measuring 15 mm in diameter within the parotid gland tissue.
  • Microscopically, the lesion featured large pools of mucin containing clusters of tumor cells with little atypia and low mitotic activity.
  • Immunohistochemically, the tumor cells showed expression of epithelial markers and of both estrogen and progesterone receptors.
  • Left lateral neck dissection revealed massive lymphogenous dissemination of the tumor.
  • Retrospective analysis of a skin biopsy from the same anatomic area performed 8 years prior to parotid neoplasm displayed a tumor with identical microscopic appearance and immunohistochemical profile (additionally performed) which was, however, misdiagnosed as a benign lesion.
  • The differential diagnostics of this rare tumor is discussed.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Head and Neck Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis. Parotid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764163.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


96. Harvey TJ, Gazi E, Henderson A, Snook RD, Clarke NW, Brown M, Gardner P: Factors influencing the discrimination and classification of prostate cancer cell lines by FTIR microspectroscopy. Analyst; 2009 Jun;134(6):1083-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing the discrimination and classification of prostate cancer cell lines by FTIR microspectroscopy.
  • In this study we obtained Fourier transform infrared (FTIR) spectra of fixed prostate cell lines of differing types as well as the primary epithelial cells from benign prostatic hyperplasia (BPH).
  • Following on from these results the possible influences of different factors on the discrimination and classification of the prostate cell lines were examined.
  • Secondly, differences in the nucleus-to-cytoplasm (N/C) ratio were examined, and it was concluded that this factor was not the main reason for the discrimination and classification of the prostate cancer (CaP) cell lines.
  • In conclusion, given the fact that neither growth media nor N/C ratio could totally explain the classification it is likely that actual biochemical differences between the cell lines is the major contributing factor.
  • [MeSH-minor] Cell Line, Tumor. Cell Nucleus / metabolism. Culture Media. Cytoplasm / metabolism. Discriminant Analysis. Humans. Male. Multivariate Analysis. Principal Component Analysis. Spectroscopy, Fourier Transform Infrared

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19475133.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0500966
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media
  •  go-up   go-down


97. Wang Y, Wang Y, Cheng C, Ji Y, Zhao Y, Zou L, Shen A: Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma. J Cancer Res Clin Oncol; 2009 Jul;135(7):951-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma.
  • PURPOSE: The aim of the present study was to examine whether Jab1 expression is correlated with p27 protein and its phosphorylation status as well as how it might be clinically relevant in epithelial ovarian carcinoma.
  • METHODS: Immunohistochemical and Western blot analysis were done in 70 cases of epithelial ovarian cacinoma and HO-8910 cells.
  • RESULTS: Jab1 overexpression was detected in 84.3% (59 of 70) of malignant tumors and 31.6% (6 of 19) of benign tumors.
  • A positive correlation between Jab1 and cytoplasmic p27 as well as Ser10 phosphorylated p27 was found in malignant ovarian tumors.
  • What is more, increased expression of a phosphorylated histone H1 in the immune-complex obtained from Jab1 transfected HO-8910 cells was also observed.
  • CONCLUSIONS: Jab1, as a negative regulator of p27, may be associated with the progression and prognosis of epithelial ovarian tumors.
  • [MeSH-minor] Adult. Aged. Cyclin-Dependent Kinase 2 / metabolism. Disease Progression. Female. Humans. Middle Aged. Phosphorylation. Prognosis. Protein Binding. Protein-Serine-Threonine Kinases / metabolism. Serine / metabolism. Transfection. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. L-SERINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1997 Sep 1;16(17):5334-44 [9311993.001]
  • [Cites] J Cell Physiol. 2000 Apr;183(1):10-7 [10699961.001]
  • [Cites] Trends Cell Biol. 2001 Oct;11(10 ):420-6 [11567875.001]
  • [Cites] Curr Opin Cell Biol. 2000 Dec;12(6):676-84 [11063931.001]
  • [Cites] Nature. 1999 Mar 11;398(6723):160-5 [10086358.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25146-54 [10831586.001]
  • [Cites] Nat Med. 2002 Oct;8(10 ):1145-52 [12244301.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5652-9 [14654548.001]
  • [Cites] Science. 1995 Aug 4;269(5224):682-5 [7624798.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 1;347(3):601-7 [16842750.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2977-81 [12782606.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1136-44 [12244303.001]
  • [Cites] Genes Dev. 1997 Jun 1;11(11):1464-78 [9192873.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8132-41 [15623586.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8581-9 [16951171.001]
  • [Cites] Cancer J. 2002 May-Jun;8 Suppl 1:S22-30 [12075699.001]
  • [Cites] J Biol Chem. 2002 Jan 18;277(3):2302-10 [11704659.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17 ):14355-8 [11889117.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2635-43 [12050228.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1153-60 [12244302.001]
  • [Cites] Cell. 1994 Jul 15;78(1):59-66 [8033212.001]
  • [Cites] EMBO Rep. 2001 Feb;2(2):96-101 [11258719.001]
  • [Cites] Nature. 1998 Nov 12;396(6707):177-80 [9823898.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4130-5 [11751512.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1672-7 [8939849.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):453-7 [8837781.001]
  • [Cites] EMBO J. 2001 Dec 3;20(23 ):6672-82 [11726503.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6583-91 [11522658.001]
  • [Cites] Oncology. 2003;65(4):355-62 [14707456.001]
  • (PMID = 19139918.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 452VLY9402 / Serine; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 3.4.- / Peptide Hydrolases; EC 3.4.-.- / COPS5 protein, human
  •  go-up